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ABSTRACT - Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by a
progressive decline in cognition and memory, leading to significant impairment in daily activities and ultimately
death. It is the most common cause of dementia, the prevalence of which increases with age; however, age is not
the only predisposing factor. The pathology of this cognitive impairing disease is still not completely
understood, which has limited the development of valid therapeutic options. Recent years have witnessed a wide
range of novel approaches to combat this disease, so that they greatly increased our understanding of the disease
and of the unique drug development issues associated with this disease. In this paper, we provide a brief
overview of the history, the clinical presentation and diagnosis, and we undertake a comprehensive review of the
various approaches that have been brought to clinical trials in recent years, including immunotherapeutic
approaches, tau-targeted strategies, neurotransmitter-based therapies, neurotropic and hematopoietic growth
factors, and antioxidant therapies, trying to highlight the lessons learned from these approaches.
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
_______________________________________________________________________
approaches. In this manuscript, we focus mainly on
the therapeutic approaches that have entered clinical
trials.

INTRODUCTION
The progressive growth of the elderly population
associated with constant increase in life expectancy,
our limited understanding of the underlying
mechanisms involved in the etiology of the disease,
and the lack of reliable and effective preventive and
disease-modifying therapies available, has rendered
Alzheimer’s disease (AD) one of the great health
challenges of the 21st century.
AD is an
irreversible neurological disorder that destroys
cognitive function including loss of memory,
judgment, reasoning, and behavioral control (1). It
has serious impact on social functioning, disruption
of quality of life, and impairment of activities of
daily living. It is the most common cause of
dementia that begins slowly and worsens over time
with a prevalence that increases with age (2). A
complex set of cellular events, including feedback
and feedforward responses of astrocytes, microglia,
and vasculature might be involved in the etiology of
AD, which has recently been reviewed by Strooper
and Karran (3). Increased understanding of the
underlying mechanisms involved in the etiology of
the disease during past two decades has led to the
development of a wide range of novel therapeutic

History
Age-related dementia has been recognized since
ancient times. One of the earliest references to
dementia occurring with age is attributed to
Pythagoras, a 7th century BC Greek physician.
Pythagoras divided the human life cycle into five
stages commencing at ages 7, 21, 49, 63, and 81
years-old, describing the last two stages of life as
the “senium”, a period characterized by a regression
in mental capacity and a return to the “imbecility of
the first epoch of infancy” (4). In 500 BC, the
Greek Judge Solon recognized the impairments on
decision making process that could be brought upon
by old age, revised laws regarding inheritances and
added the provision that “judgment … [be] not
_________________________________________
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cause of death calling it a “major killer” (7). In
1993, apolipoprotein E (APOE), which is located on
chromosome 19, was the first gene found to be
related to the risk of Alzheimer`s. Other genes
were subsequently found to be linked to AD (8)
identifying possible genetic etiologies for some
forms of AD.

impaired by pain, violence, drugs, old age, or the
persuasion of a woman” in the making of wills (5).
In the 13th Century, Friar Roger Bacon recognized
that “age is the home of forgetfulness” and that loss
of memory and cognitive function was related to a
disorder of the brain and not the heart, dispelling
common notions of that time (4). However, he
further recognized that specific cognitive deficits
may be attributed to injuries in different brain areas
(6). Dementia, as an abnormal process of aging
was first recognized in 1901 by Dr. Alois
Alzheimer, after whom Alzheimer’s disease is
named. At that time, Dr. Alzheimer began treating a
51-year old woman named Auguste who had
symptoms of short-term memory loss and
confusion. Dr. Alzheimer followed her case until
she died in 1906, after which he studied her brain
and determined that her problem was not caused by
normal dementia due to aging, but a larger health
issue. She was the first confirmed case of
Alzheimer’s disease. In 1976, neurologist Dr.
Robert Katzman, a pioneer in Alzheimer’s research,
identified Alzheimer’s as the most common form of
dementia and proposed that it may be a common

Epidemiology
It is estimated that approximately 44 million people
worldwide are living with Alzheimer's disease.
However, only 11 million have been officially
diagnosed with AD. Women are more likely to
develop Alzheimer's disease than men of the same
age. Alzheimer's disease is most common in
Western Europe, followed by North America, and is
least prevalent in sub-Saharan Africa (9). The
global cost of AD and dementia was estimated at
605 billion dollars in 2015. From 2000-2013, AD
was the 6th leading cause of death in the United
States (10), and it is expected to be the third leading
cause of death of elderly after cancer and heart
disease. AD is also the only disease in the top ten
causes of death that cannot be stopped,

Figure 1. Statistical data for Alzheimer’s disease in United States, based on the data extracted from [10].
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cured, or prevented. Among 5.3 million Americans
with AD, 5.1 million are aged 65 and older. Figure
1 summarizes the distribution of AD based on age,
gender, and race.

of AD include amyloid deposits consisting of
amorphous aggregates of misfolded amyloid-beta
(Aβ) protein (29). The “Amyloid Hypothesis”
assumes a central role for Aβ in the pathogenesis of
AD and characterizes AD as a “protein misfolding
disease” which leads to aggregation and toxic
accumulation of Aβ in the brain (17, 18). However,
although accumulation of Aβ has been linked to
AD; the role of the protein in AD is not entirely
clear.
Aβ is produced from a precursor protein known
as amyloid precursor protein (APP), a highly
conserved membrane protein mainly expressed
around the synapse of neuronal tissue (19). APP
seems to be involved in neuronal plasticity and
synapse formation (20). It is metabolized via two
distinct pathways: (i) non-amyloidogenic pathway
(due to the non-aggregating nature of the products);
and (ii) amyloidogenic pathway responsible for Aβ
synthesis.
The non-amyloidogenic metabolic
pathway is initiated by α-secretase and further
processed by γ-secretase, which are members of a
family of proteolytic proteins with a disintegrin and
metalloprotease domain (ADAM) (21).
The
amyloidogenic pathway is initiated through
cleavage of APP by β-secretase (also known as
beta-site APP cleaving enzyme; BACE1), and again
processed by γ-secretase (22). The Aβ fragments
from the amyloidogenic pathway accumulate to
form hard, insoluble plaques that are toxic to
neurons, and can lead to neuronal death.
Aβ clearance is also affected by the
Apoliprotein E (ApoE), a lipid binding protein
involved in the transportation of cholesterol and
triglycerides to different tissues, including brain
(23). Aβ binds to various regions of ApoE, and
each Aβ-ApoE complex then participates in a
different metabolic pathway, which includes: (1)
clearance by the brain blood barrier; (2) degradation
by amyloid degrading enzyme (ADE); and, (3)
deposition of Aβ into the cells. ApoE exists in
different isomers, and each Aβ–ApoE complex is
believed to have different rates of catabolism.
Catabolism of Aβ-Apo E4 has been found to be
specifically reduced with age, leading to reduced
availability of ApoE in brain, which in turn results in
accumulation of toxic cholesterol and Aβ oligomers,
increasing the risk of AD (24), while Apo E2 and
APO E3 eliminate Aβ by degradation or transport
(25). This mechanism is illustrated in Figure 2
(reproduced from (26)).

Etiology
The etiology of AD is uncertain; however, genetics,
environmental, and developmental components are
likely to play a role. The greatest risk factor for AD
is advancing age, although genetics has also been
extensively studied. Mutations in three genes,
amyloid precursor protein (APP), presenilin (PS)-1
and PS-2 (both affecting APP processing and
production of amyloid-beta peptides), cause earlyonset (<60 years) autosomal dominant AD. Early
onset-AD, however, accounts for only 1% of AD
cases (11). Late-onset AD (>60 years) has most
often been genetically linked to apolipoprotein
(Apo) E ɛ4. Apo E4 has a gene-dose effect on
increasing the risk and lowering the age of both
familial and sporadic forms of late-onset AD.
While Apo E4 is the top gene associated with late
onset-AD gene, other genes that may modulate the
risk of late-onset AD include CLU, CR1, PICALM,
BIN1, SORL1, GAB2, ABCA7, MS4A4/MS4A6E,
CD2AP, CD33, APHA1, and HLA-DRB1/5. Other
risk factors for AD include head trauma, female
gender, learning disabilities, education level,
homocysteine levels, socioeconomic status, and
previous depression (12). Importantly, vascular risk
factors including diabetes and hyperlipidemia are
additional risk factors for AD (13, 14). However,
age and the Apo E4 allele continue to be the most
significant risk factors for the development of AD
along with female sex (15). The greater prevalence
of AD in women could be attributed to the higher
life expectancy in women, since the incidence of
AD in earlier ages is comparable between sexes
(16).
Pathophysiology of AD
AD is a progressive neurodegenerative brain
disorder. At the cellular level, AD is characterized
by a progressive loss of cortical neurons most
notable in the entorhinal cortex, hippocampus and
posterior cingulate cortex (12). The neuronal
damage is believed to be related to the deposition of
abnormal proteins, which are the hallmark
pathological lesions of AD known as the “plaques”,
found in the extracellular space, and “tangles”,
inside the cells. The neurotic plaques characteristics
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Figure 2. LRP1 mediates efflux of unbound Aβ and Aβ bound to ApoE2, ApoE3 or α2M from the brain parenchyma into
the blood with the help of ABCB1; ApoE4 inhibits this transport process. Figure reprinted with permission from TarasoffConway JM, et al. Nat Rev Neurol. 2015;11(8):457-70 [26].

Although abnormal aggregation and deposition
of Aβ has attracted popular attention in the last
decade as the primary causative mechanism of AD,
it has been proposed that a second mechanism
might play an equally important role in the
pathophysiology of AD (27) via formation of
neurofibrillary tangles. These tangles are insoluble
fibers found within the somatodendritic and axons
in AD patients (28). Neurofibrillary tangles
primarily consist of abnormal aggregation of a
protein called tau. Tau was originally recognized as
the main microtubule-associated protein in the
mammalian brain in 1975 (29), and is mostly
expressed in axons, where it stabilizes the

microtubules and promotes transportation of
nutrients and other important molecules. Axon
deficits observed in AD have been at least partially
linked to aberrant hyperphosphorylation of tau,
which reduces the capability of Tau in stabilizing
the microtubules (27). In AD, hyperphosphorylated
tau has been identified as the primary component of
the neurofibrillary tangles (30, 31). The formation
of these tangles correlates with the severity of AD
(32, 33). It has also been shown that ApoE ɛ4 is
associated with increased tau accumulation (28).
Clinical features of Alzheimer’s Disease
AD is characterized by a progressive loss of
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phases appear. Therefore, literature suggest that
AD should be divided into three phases: (a) Preclinical AD: Very early signs and symptoms:
patient has more memory problems than normal,
but symptoms are not severe, and their ability to
participate in normal daily activity is not impaired
(39); (b) Mild cognitive impairment (MCI): mild
changes in thinking and memory, but daily activity
is not compromised. Patients are often diagnosed in
this stage (40); and (c) Clinical AD: thought,
behavior and memory symptoms that impair daily
activity and life (41). Use of the aforementioned
biomarkers and other biomarkers that measure
neuronal
integrity,
amyloid
plaques
and
neurofibrillary tangles (which are present before
cognitive deficits) will help to identify AD patients
prior to symptoms and pave the way for early
treatment.

memory and other cognitive functions that over
time lead to aphasia, apraxia, agnosia, and reduced
visual perception. Changes in memory and daily
activity are usually the first changes noted at the
time of diagnosis, although many patients may also
display other subtle symptoms of cognitive
impairment (34, 35). These include symptoms such
as forgetting words, difficulty remembering names,
reduced ability to solve daily problems, and
geographic disorientation to the extent that an
Alzheimer’s patient will usually lose his way home
(36). In later stages, neuropsychiatric symptoms
appear including depression, agitation and
hallucinations with gradual and progressive loss of
self-awareness and insight (36). In early stages a
patient can care for his/her basic needs and can
participate in some activities and hobbies. During
the late stages of the disease, patients lose the
ability to manage basic activities of daily life, such
as personal hygiene, toileting, eating, and dressing.
The duration from the onset of the disease to death
is approximately 7 years (37).

Therapeutic Approaches
The non-pharmacological approaches to prevent
AD include relaxing activities, such as listening to
music or cooking that are speculated to improve the
neural efficacy of cognitive processing and
emotional and behavioral functioning (42). On the
other hand, the therapeutic agents currently in the
market do not impact the progression of AD and are
only expected to alter the cognitive symptoms,
which appear in later stages of AD. In the next
sections we will review the most recent attempts in
search for more effective therapeutic approaches.

Diagnosis of AD
There is no specific test to detect Alzheimer’s
disease, and the diagnosis is based on clinical
history obtained from the patient and the patient’s
family. Assessment of cognitive function by mental
status examination is a necessary component of AD
diagnosis.
Patients diagnosed with AD are
classified based on criteria as probable AD or
possible AD with and without evidence of AD
pathophysiologic processes. Laboratory and
neuroimaging studies are used as an adjunct to the
clinical criteria for AD. Brain imaging studies such
as MRI and PET scans, can support the diagnosis of
AD, only if there is evidence of abnormality such as
brain atrophy or decreased fluorodeoxyglucose
(FDG) uptake on PET, as biomarkers for
neurodegeneration and evidence of the downstream
effects of AD pathophysiologic processes (Figure
3; (38)). Positive PET amyloid imaging can also
contribute to the clinical diagnosis of AD.
Laboratory studies such as low CSF AB42, also a
biomarker of brain amyloid-beta protein deposition
and elevated CSF tau (total and phosphorylated),
are also evidence of AD pathophysiologic
processes.
Currently, AD can only be diagnosed based on
symptoms.
However,
the
pathophysiologic
processes of AD begin long before the symptomatic

Beta Amyloid Therapy
Active immunotherapy
Active immunization (vaccination) against Aβ is
one of the therapeutic approaches for AD that has
been pursued in the past two decades. Active
immunization against Aβ1-42 (the predominant
form of beta-amyloid found in the senile plaques of
AD) in mouse models of AD has been successful in
prevention and reversal of amyloid plaques,
neurotic dystrophy, synaptic loss, and gliosis with
correlating improvement of impaired behavioral
performance. Active immunization was first
attempted in humans in 2000 with the firstgeneration vaccine AN-1792, a synthetic full-length
Aβ1-42 peptide linked to QS-21, a carrier made of
inactivated diphtheria toxin for stimulation of
immune system. This first attempt caused an aseptic
meningoencephalitis observed in 6% (18/300) of
vaccinated patients (43).
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Figure 3. Neuroimaging studies: a, compared with the normal brain of a healthy person on the right, the brain of an
Alzheimer’s disease patient exhibits marked atrophy as evidenced by the increased prominence of the sulci and gyri on the
surface of the AD brain, particularly in the temporal and frontal lobes; b, Sagittal positron emission tomography (PET)
images of a normal and AD brain show glucose uptake in a normal control subject on the left (red and yellow indicate high
levels of glucose uptake), while the brain of Alzheimer’s patient on the right exhibits large decreases in energy metabolism
in the frontal cortex (top of PET image) and temporal lobes (sides of PET image). Reprinted from [38].

with only 20% of patients producing a significant
antibody response primarily against the N-terminus.
However, a later 4.6 year follow-up revealed that
vaccinated AD patients reported a functional benefit
in the years after vaccination and postmortem
pathology examination of vaccinated patient brains
found marked clearance of insoluble amyloid

This was later attributed to a T-cell mediated
response to Aβ residues 15-42 and the phase II trial,
which began in AD patients in late 2001 was
terminated just a few months into the trial in early
2002 (NCT00021723). Further supporting early
termination was data showing that the
immunological response to the vaccine was weak,
189
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term extension studies were terminated in 2013
(NCT0096053, NCT01238991).
Affitope AD-02, directed against a slightly
shorter Aβ peptide sequence fragment, Aβ1-6, was
derived from a proprietary method termed
AFFITOPE-technology that produces “non-self”
proteins and uses aluminum hydroxide as an
immunological adjuvant believed to be able to
avoid the adverse effects noted with the other active
vaccines. This vaccine reached human trials in late
2000s (47, 48) with phase Ia/Ib studies showing
favorable safety and tolerability even after 2 years
despite
some
concerns
with
ARIA-E
(NCT00633841,
NCT01093664,
and
NCT00711321). A phase II trial of AD-02 plus an
undisclosed immunomodulator was conducted from
2010-2013 and compared AD-02 to placebo and to
the immunomodulator itself (NCT01117818) in
patients with AD. The trials showed favorable
safety and tolerability but primary and secondary
outcome measures were not met in the AD-02
group and a subsequent phase II study and
observational follow-up study was terminated
(NCT02008513, NCT01357629). Surprisingly,
however, the company announced in a news release
benefit in the placebo group that received the
immunomodulator by itself and has renamed this
immunomodulator AD-04 and is pursuing
development of this agent.
V-950 is an Aβ amino terminal peptide
formulated on an aluminum-containing adjuvant
along with Iscomatrix™ an improved saponin
adjuvant with antigen delivery and presentation
properties as well as immunomodulatory
capabilities (49). Iscomatrix™ was shown to be
able to rapidly traffic antigens into the cytosol of
multiple dendritic cell subsets, induce the induction
of various cytokines and chemokines, and link
innate and adaptive immune responses in vivo in a
toll-like
receptor-independent
but
MyD99dependent manner to provide enhanced and
accelerated immune responses including a response
from a range of subclasses of antibodies as well as
CD4+ and CD8+ T-cells (50). A phase I, doubleblind, randomized, placebo-controlled, dose
escalating study to evaluate the safety, tolerability,
and immunogenicity of the compound started
enrolling 86 patients in 2007 with a planned study
completion date of January 2012 (NCT00464334).
The authors were unable to find any reports on the
results for this trial.

plaques. Phospho-tau analysis showed a reduction
of aggregated tau in neuronal processes (44). These
findings encouraged further development of other
candidates that would avoid the above problems for
active vaccination.
Second-generation vaccines have been designed
using shorter Aβ peptide segments directed at the
N-terminal end of the Aβ protein, which was
believed to contain a B-cell epitope while avoiding
T-cell activation from Aβ residues 15-42. Many of
these second generation vaccines including ACC001, Affitope AD-02, V-950, and ACI-24 have
undergone phase II trials as detailed below. Others,
including MER5101, UB-311, Lu AF20513, and
CAD 106 are in various stages of preclinical, phase
I, II, and phase II/III testing respectively as detailed
in Table 1. Each of these compounds are associated
with unique drug development strategies relayed
below.
ACC-001, also known as vanutide cridificar,
was designed as a conjugate of multiple short Aβ
fragments consisting of amino acids 1-7 again
linked to QS-21 (similar to the first generation
vaccine AN-1792) for immune stimulation.
Vanutide was tested in patients with mild-tomoderate AD in multiple phase II trials in the mid
to late 2000s (NCT01284387, NCT00955409,
NCT00752232, NCT00498602, NCT01227564,
NCT00479557, and NCT00959192). In the trials,
more than 90 percent of participants in the active
groups responded to the vaccine by making
antibodies, which was an improvement over AN1792 in which only 20% of participants responded
by making antibodies. However, the molecule was
still plagued by side effects including amyloidrelated imaging abnormalities with vasogenic
edema (ARIA-E), indicative of potential new
microhemorrhages, occurring in two (0.8%)
patients. Despite the occurrence of ARIA-E, which
would prove to be consistently associated with most
if not all of the active vaccines, the molecule was
concluded to have an acceptable safety profile.
Further
exploratory
cognitive
evaluations,
volumetric brain MRI, and CSF biomarkers,
however, did not show differences between
treatment groups and placebo although some trends
were seen including less brain amyloid
accumulation in vaccinated patients as assessed by
PET imaging and slight reductions in CSF
phosphorylated tau (45, 46). The development of
this vaccine is not being further pursued and long
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epitopes are believed to stimulate a T helper cell
response that induces B cells to make antibodies to
Aβ. This approach addresses the challenges seen
with prior Alzheimer’s vaccines which have been
unable to produce successful antibody responses in
the immune systems of elderly people whose pool
of naïve T cells who can take on a new antigen is
low. Patients who carry pre-existing memory T
helper cells that recognize tetanus epitopes are
expected to be able to mount a strong response to
this recombinant epitope vaccine. In animal models,
Lu AF20513 was found to induce robust "non-self"
T-cell responses and induce production of anti-Aβ
antibodies (53). This vaccine is currently recruiting
for phase I clinical trials in an open-label, doseescalation study to assess its safety, tolerability and
immunogenicity expected to be completed in 2017
(NCT02388152).
The vaccine, UB-311, is an equimolar mixture
of 2 synthetic peptides coupled through an
oligonucleotide spacer to Aβ1-14. In animals, UB311 produced better antibody responses than did
Aβ1-14 or Aβ1-28 alone or Aβ1-14 coupled to
keyhole limpet hemocyanin, a very large,
immunogenic carrier molecule and also decreased
the amount of Aβ deposited in brain with
improvement in learning and short-term memory in
AD animal models. In a phase I trial and
observational extension phase trialconducted in
YEAR, 19 Taiwanese AD patients showed
cognitive improvement on various measures with an
acceptable safety and tolerability profile (54). UB311 is now in a phase IIa randomized, double-blind,
placebo-controlled trials designed as a 3-arm
parallel-group, multicenter study to evaluate its
safety, tolerability, immunogenicity, and efficacy
starting October 2015 with an expected completion
date of December 2017 (NCT02551809).
CAD106 combines multiple copies of Aβ1-6
coupled to a Qβ virus-like particle. A phase I trial
in 58 Swedish patients in 2008 (NCT00411580)
concluded that the vaccine was able to induce
appropriate Aβ IgG titers and was generally safe
and
well-tolerated
with
no
reports
of
meningoencephalitis (55). CAD106 has since been
tested in five multicenter phase II trials
(NCT01097096, NCT00956410, NCT00795418,
NCT01023685, NCT00733863) in the United States
and Europe including a 90-week trial, and two 66week extension trials exploring intramuscular and
subcutaneous injections and additional doses of

ACI-24 is a liposome vaccine based on the
truncated Aβ1-15 sequence that grew out of work
with tetrapalmitoylated preparations of N-terminal
Aβ fragments which showed that these preparations
rapidly stimulated anti-Aβ antibodies that could
dissolve amyloid fibers in vitro and in vivo. The
vaccine consists of an array of Aβ1-15 sequences
that are sandwiched between palmitoylated lysines
at either end and are anchored onto the surface of
the liposomes so that the peptides adopt an
aggregated
β-sheet
structure,
forming
a
conformational epitope (51). A Phase I/II doubleblind, randomized, placebo-controlled, adaptive
design study of the safety, tolerability,
immunogenicity and efficacy of ACI-24 was
initiated in 2009 and enrolled 198 AD patients at
five sites in Finland, Sweden, and Denmark
(EUCTR2008-006257-40-FI). Patients were treated
for one year and followed for two or more years.
No results have been announced, although the
company has recently launched a phase I trial of
ACI-24 in Downs Syndrome patient suggesting an
acceptable safety and tolerability profile of ACI-24
(NCT02738450).
MER5101 is a novel conjugate of Aβ1-15 also
conjugated to diphtheria toxoid (DT), and
formulated in a nanoparticular emulsion-based
adjuvant. It has currently only been evaluated in
animal models but the evidence in these models
suggest potential for development. High IgG1 and
IgG2b antibody responses have been observed in
animal models, suggesting a Th2-biased response.
A strong proliferative response was observed when
splenocytes were re-stimulated with the Aβ1-15:DT
conjugate, whereas proliferation was absent after
re-stimulation with Aβ1-15 or Aβ1-40/42 peptides,
indicating a cellular immune response against DT
while avoiding an Aβ-specific T-cell response.
Moreover, significant reductions in cerebral Aβ
plaque burden, accompanied by attenuated
microglial activation and increased synaptic
density, and improvement in cognitive deficits in
contextual fear conditioning and the Morris water
maze were observed. It is not known whether it will
move forward into human trials (52).
LuAF20513 is an engineered protein in which
Aβ1–12 is repeated three times, interspersing each
with a stretch of the P30 and P2 Th epitopes from
the tetanus toxin conventional vaccine. As most
adults have memory T cells that recognize the toxin
from prior tetanus inoculation the tetanus toxin
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function in the phase II study, post-hoc exploratory
efficacy analyses hinted at a treatment response in
Apoε4 non-carriers and some biomarkers did show
trends towards improvement, including a trend
towards reduction of CSF P-tau and reduction in
cortical fibrillar Aβ as assessed by serial amyloid
PET (58-60).
Two 18-month phase III trials (NCT00574132,
NCT00575055) enrolling a total of 2,452 patients
who were Apoε4 carriers and non-carriers
respectively, were then completed in 2013. Both
trials failed to show a treatment effect on cognitive
or functional primary outcomes or rate of brain
volume loss (61). Reductions were seen in CSF ptau and amyloid binding as measured by PET was
not increased from baseline, but this was seen in
APOε4 allele carriers only and not in non-carriers.
Furthermore, while treatment seemed to prevent
increases in plaque buildup, there was no reduction
of amyloid binding, indicating that while plague
aggregation may have been prevented, clearance of
plaque may not have been stimulated. Additionally,
ARIA-E was found to occur with increased
bapineuzumab dose and Apoε4 allele number,
believed to be in part due to increase Aβ load,
including vascular Aβ load, in those with increased
ApoE4 allele number, which ultimately led to
discontinuation of the highest 2 mg/kg dose. Two
other phase III trials were terminated on August 6,
2012 because of this lack of clinical benefit, though
not necessarily because of any new safety concerns
(NCT00667810, NCT00676143).
Failure of
bapineuzumab to achieve clinical benefit has been
attributed to the dose-limiting ARIA-E adverse
effect as well as to late-stage treatment (62).
Solanezumab was the second monoclonal
antibody to enter advanced clinical development.
Solanezumab is targeted against Aβ 16–24 and
unlike bapineuzumab binds with picomolar affinity
only to the monomeric, soluble, toxic species of Aβ.
Solanezumab binds soluble Aβ in both the
periphery and the brain thereby driving the
equilibrium toward the soluble form, putatively
resulting in resolution of Aβ plaques (63).
Solanezumab may also have reduced frequency of
adverse effects such as ARIA compared to
bapineuzumab as evidenced even from the very first
human trial in which no MRI evidence of

vaccine and adjuvants with different longerinjection/booster-shot regimens (56). In a unique
study design compared to the design of prior active
vaccines, a phase II/III trial began in November
2015 and is expected to enroll 1,340 homozygous
ApoE4 carriers who are cognitively normal to a 5year treatment period with an expected completion
date in 2023 and will measure the ability to delay
diagnosis to MCI or AD dementia (NCT02565511).
Besides progressive modifications in the structure
and activity of AD molecules, a similar trend
towards study designs that target AD at earlier and
earlier stages will also be seen in the development
of other therapeutic approaches as well.
Passive immunotherapy
Passive immunization is currently the most widely
developed approach in clinical trials, and numerous
approaches have completed initial stages and are in
phase
III
clinical
trials.
The
passive
immunotherapeutic agents are summarized in Table
2.
Bapineuzumab was the first antibody to reach
advanced stages of clinical development.
Bapineuzumab is a humanized murine monoclonal
antibody 3D6, directed against the N-terminal
region of Aβ1-6.
Bapineuzumab binds to
aggregated Aβ and to a lesser extent soluble Aβ
with nanomolar affinity, activating microglial
phagocytosis and promoting plaque clearance in
animal models. Bapineuzumab was tested in a 12month phase I study with 80 patients
(NCT00397891) completed in 2007 and an 18month phase II study with 234 patients
(NCT00112073) completed in 2009. In these initial
safety studies, 3/10 patients on the highest dose in
the phase I study and 12 patients in the phase II
study
suffered
amyloid-related
imaging
abnormalities indicative of potential new
microhemorrhages, similar to that seen with active
immunization (57, 58). Again, despite the results of
the phase II study, bapineuzumab was deemed to be
relatively safe and well tolerated as half of the
ARIA-E cases were asymptomatic, and half
suffered only transient symptoms with just one
patient requiring steroid treatment (58). Although
no significant difference was seen between
treatment groups and placebo in the pre-specified
secondary outcome measures of cognition and
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Table 1 – A summary of the clinical trials based on active immunotherapy approaches (https://clinicaltrials.gov)
Drug name
AN-1792
(first
generation
vaccine)
ACC-001 or
vanutide
cridificar
(second
generation)

Affitope AD02 (second
generation)

V-950 (second
generation)

Clinical trial
number & Phase

Start & End
date

Trial
population

NCT00021723
Phase II

2001 - 2002

300

Phase II
clinical trials:
NCT01284387
NCT00955409
NCT00752232
NCT00498602
NCT01227564
NCT00479557
NCT00959192
NCT01117818 –
phase 2
NCT00633841 –
phase 1
NCT01093664 –
phase 1
NCT00711321 –
phase 1b
NCT02008513 –
phase 2
NCT01357629 –
follow-up
NCT00464334
phase I

2011 - 2014
2009 - 2013
2008 - 2012
2007 - 2013
2011 - 2014
2007 - 2013
2009 - 2013
2010 - 2013

126
50
40
160
63
86
32
335

2008 - 2009

24

2009 - 2010

20

2008 - 2010

23

2013 - 2014

194

2011 - 2013

11

2007 - 2012

86

Outcome
Functional benefit and marked
clearance of insoluble amyloid
plaques with reduction of
aggregated tau in neuronal
processes.
Exploratory cognitive
evaluations, volumetric brain
MRI, and CSF biomarkers did
not show differences between
treatment groups and placebo.

Special notes
Made of inactivated diphtheria toxin for
immune stimulation that caused aseptic
meningoencephalitis observed in 6%
(18/300) of vaccinated patients.
Used in combination with an adjuvant
immunostimulatory agent (QS-21).

The trials showed favorable
safety and tolerability but
primary and secondary outcome
measures were not met in the
AD-02 group and a subsequent.

Uses aluminum hydroxide as an
immunological adjuvant.

No results have been reported
for this trial.

An Aβ amino terminal peptide formulated
on an aluminum-containing adjuvant with
Iscomatrix™ an improved saponin adjuvant
with antigen delivery and presentation
properties as well as immunomodulatory
capabilities.
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Table 1 Continued…
ACI-24
(second
generation)

MER5101
(second
generation)
LuAF20513
(second
generation)

UB-311
(second
generation)

CAD106
(second
generations)

EUCTR2008006257-40-FI,
Phase I/II

2009

198

NCT02738450

2016 - 2016

24

NCT02388152
Phase I

NCT00965588Phase I
NCT01189084Patients who
previously received
UB311
NCT02551809phase II
NCT00411580Phase I
NCT01097096Phase II
NCT00956410Phase II
NCT00795418Phase II
NCT01023685Phase II
NCT00733863Phase II
NCT02565511phase II/III

Currently
recruiting
(expected to be
completed in
2017)

35

2009 - 2011

19

2010 - 2011

14

2015 - 2017

45

2005 - 2008

58

2010 - 2012

177

2009 - 2011

21

2008 - 2010

31

2009 - 2012

24

2008 - 2010

27

2015 - 2023

1340

No results have been announced,
although the company has
recently launched a phase I trial
of ACI-24 in Downs Syndrome
patient suggesting an acceptable
safety and tolerability profile of
ACI-24.

Ongoing

Conjugated to diphtheria toxoid (DT), and
formulated in a nanoparticulate emulsionbased adjuvant
Is an engineered protein in which Aβ1–12 is
repeated three times, interspersing each with
a stretch of the P30 and P2 Th epitopes from
the tetanus toxin conventional vaccine.
To Evaluate Safety, Tolerability and
Immunogenicity of Vaccine (UB 311) in
Subjects With Alzheimer's Disease

Concluded that the vaccine was
able to induce appropriate Aβ IgG
titers and was generally safe and
well-tolerated with no reports of
meningoencephalitis.
Phase III: ongoing
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month trial in patients with normal cognitive
function who are deemed at risk for AD by
florbetapir PET brain imaging initiated in 2014 that
is still actively recruiting (NCT02008357), and a
24-month trial in patients with prodromal AD or
mild cognitive impairment initiated in June of 2016
(NCT02760602). Of note, in all these ongoing
phase III trials, positivity on PET amyloid imaging
is an inclusion criterion, as a common finding in
both trials with both bapineuzumab and
solanezumab was that a quarter of patients with
mild Alzheimer’s tested negative by means of PET
amyloid imaging indicating that a quarter of the
patients likely did not have Alzheimer’s disease.
As such, using positive pet amyloid imaging as an
inclusion criterion will greatly increase the potential
to show efficacy.
Gantenerumab is another monoclonal antibody
being evaluated in AD. It is a fully human IgG1
antibody that preferentially binds to aggregated Ab
in the brain and vasculature with subnanomolar
affinity and does not alter plasma Aβ.
Gantenerumab is a conformational antibody that
possesses two binding sites, one in the N-terminus
region and another in mid-domain of the Aβ
peptide, believed to act centrally to disassemble and
degrade amyloid plaques by recruiting microglia
and activating phagocytosis (69). Indeed, much
initial excitement accompanied the very first in
human studies of gantenerumab as treatment
resulted in a dose-dependent reduction in brain
amyloid level, as assessed by percent change in the
ratio of regional carbon 11-labeled Pittsburgh
Compound B retention measured by PET. Safety
wise, four Phase 1 trials (NCT00531804,
NCT01656525, NCT02133937, NCT01636531)
conducted internationally in a total of 308 patients
suggested that gantenerumab was generally safe and
well-tolerated, although ARIA was observed (70).
Phase II/III trials of gantenerumab were
initiated in July 2010 and enrolled 799 patients
(SCarlet RoAD NCT01224106) and was the first
large trial to utilize new diagnostic criteria by the
International Working Group to enroll a
homogenous population of early symptomatic
patients whose memory deficit was likely due to
underlying Alzheimer's pathology including
patients whose MMSE was above 24 but had a
deficit on the FCSRT memory test with CSF
evidence of Aβ deposition and positivity on
amyloid PET. Dosing in this trial was discontinued

inflammation,
vasogenic
edema,
or
microhemorrhage was observed in the first 19
patients administered a single dose of solanezumab.
Later phase II single dose studies (NCT00329082,
NCT00749216) completed in 2008 and 2009 (64,
65) and an additional phase II, randomized, doubleblind, placebo-controlled trial evaluating patients
exposed to repeated doses completed in 2012
(NCT01148498), confirmed the antibody's safety
and tolerability. This later phase II trial showed no
benefits in secondary clinical outcome measures
and CSF and MRI biomarkers at the end of the 12week treatment period (66); however, it showed
dose-dependent increases in unbound CSF Aβ1-42
suggesting that solanezumab may shift Aβ
equilibria and mobilize Aβ1-42 from amyloid
plaques.
Phase III trials were initiated in 2009
[EXPEDITION1 (NCT00905372), EXPEDITION2
(NCT00904683)] enrolling 2040 AD patients from
16 countries with mild to moderate AD. When all
patients were considered, solanezumab failed to
show benefit in the primary clinical outcome
measure. However, when only patients with mild
disease were analyzed in a pre-planned subgroup
analysis, improvements in multiple cognitive and
functional scales including the 14-item Alzheimer’s
Disease Assessment Scale (ADAS-Cog14) and the
Alzheimer's Disease Cooperative Study-Activities
of Daily Living scale (ADCS-ADL) were seen,
suggesting that positive therapeutic effects were
possible if treatment was given at an early stage of
AD (67). Plasma/cerebrospinal fluid biomarker
findings also indicated target engagement by
solanezumab and the incidence of ARIA with
edema or hemorrhage was not significantly
different from placebo (67, 68).
Based on these findings, an additional phase III
trial [EXPEDITION3 NCT01900665] was initiated
in July 2013 and has finished target enrollment of
2100 patients with mild Alzheimer’s disease.
ADAS-Cog14 and the ADCS-ADL scale are the coprimary outcome measures in this trial with a
primary completion date expected in October 2016
and a study completion date expected in October
2018 (NCT01900665). Three other phase III trials
in specific subset populations have also recently
been initiated including a 48-month trial in patients
with dominantly inherited AD initiated in 2012 with
an expected completion date in 2019 that has
finished actively recruiting (NCT01760005), a 38-
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biomarker study called BLAZE was also completed
in spring 2014 (NCT01397578) and both continue
into an open-label extension trial of 361 patients
that is expected to be completed in 2017
(NCT01723826). The BLAZE study reported no
differences in PET amyloid imaging between
groups although differences were observed in CSF
Aβ. A phase II trial aiming to evaluate the safety
and efficacy of crenezumab in asymptomatic
carriers of E280A autosomal-dominant mutation of
PSEN1 for which pathological aggregation of Aβ
appears at an age of approximately 25 commenced
in November 2013 (NCT01998841). A phase III
trial was initiated Mar 2016 in 750 patients with
prodromal and mild AD (NCT02670083) and is
actively recruiting.
Aducanumab (BIIB037) is a monoclonal
antibody targeting aggregated forms of Aβ protein,
with high-affinity, fully human IgG1 monoclonal
antibody against a conformational epitope found on
Aβ. A phase Ib study of aducanumab in patients
with prodromal or mild Alzheimer’s was
completed, which showed a statistically significant
reduction on amyloid plaque as well as a
statistically significant slowing of clinical
impairment. A second Phase Ib study however,
could not replicate this and also show worsened
safety data. In summer of 2012, PRIME, a
multicenter, multiple-dose study in 166 people with
prodromal or mild AD was initiated and interim
results were promising enough that two 18-month
phase III studies were initiated in 2015 with an
expected completion date in 2022. The ENGAGE
and EMERGE studies will enroll 1,350 people with
MCI due to AD or mild AD as ascertained by a
positive amyloid PET scan each in sites in North
America
and
Europe
(NCT02484547,
NCT02477800).
Ponezumab (PF-04360365) is a humanized
IgG2δA monoclonal antibody that unlike the other
monoclonal antibodies binds the free carboxyl
terminal of amino acids 33-40 of the Aβ 1-40
peptide (72). Five phase I trials showed acceptable
safety but two phase II trials concluded in 2011
showed no treatment effect and development of
ponezumab for AD is no longer being pursued
although its use is being explored in patients with
cerebral amyloid angiopathy.
BAN2401 is a humanized IgG1 monoclonal
antibody that binds selectively to large, soluble Aβ
protofibrils and is thought to lead to their clearance

on December 19, 2014, based on an interim futility
analysis that suggested no benefit. However,
patients continued assessment and in July 2015,
Roche reported that in the fastest progressors who
also received the highest doses there was a trend
towards benefit observed in ADASCog and MMSE
scores, brain amyloid load, CSF total tau, and CSF
p-tau measures. The main side effect was ARIA
which was as high as 14% but was mostly
asymptomatic and associated with gantenerumab
dose and with the number of ApoE 4 alleles a
patient carried. The trial now continues as an open
label trial of the higher gantenerumab dose with an
expected completion date in 2020. A second phase
III trial initiated in 2014 is also ongoing with a
higher dose and has completed recruitment of 389
patients with mild AD and is expected to be
complete
in
2019
(Marguerite
Road
NCT02051608). Gantenerumab, together with
solanezumab, is also being investigated by the
Dominantly Inherited Alzheimer Network (DIAN).
Crenezumab (MABT5102A) is another
humanized
monoclonal
antibody
under
development for AD. Crenezumab is an IgG4
monoclonal antibody which is expected to reduce
pro-inflammatory activity and limit risk of
vasogenic edema due to reduced effector functions
on microglia (71). Crenezumab binds all forms of
Aβ, including monomers, oligomers, and fibrils but
binds with highest affinity to the oligomers and
fibrils inhibiting aggregation and promoting
disaggregation. Phase I trials were initiated in 2008
and 2009 in a total of 78 patients (NCT00997919,
NCT00736775). No results have been published
for phase I trials but safety and tolerability was such
that a large multi-center 68-week phase 2 trial
enrolling 448 patients in North American and
Europe with mild to moderate AD was initiated in
2011 and completed in 2014 (ABBY
NCT01343966). In this study both subcutaneous
and intravenous administration was assessed.
Intravenous administration allowed for almost twice
as much delivery of antibody as the subcutaneous
administration as dosing was not limited by fears of
T-cell mediated inflammation and resulting ARIA.
Despite this increased drug exposure, ABBY did
not show differences in primary clinical endpoints
of cognitive change when assessing the total
population of mild-to-moderate AD although
further analysis suggested possible efficacy when
only mild AD was considered. A 91-patient
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have numerous toxic consequences (76).
Furthermore, the active site of BACE1 is relatively
large, and many of the bulky compounds that are
needed to inhibit BACE1 activity are unlikely to
cross the blood–brain barrier. Therefore, much
effort has been put into developing nonpeptidomimetic β-secretase inhibitors that show
high
BACE1
selectivity
(BACE1/BACE2
selectivity >100) with weak or non-peptide
characteristics that favor CNS penetration and oral
bioavailability (77). Many BACE inhibitors are still
in the preclinical phase and only a few have entered
clinical trials to date. Clinical trials involving βsecretase inhibitors are summarized in Table 3.
The BACE1 inhibitor furthest along in
development is MK-8931, which is a diaryl amidesubstituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide
derivative and a small molecule inhibitor of
BACE1/2 (with a higher affinity towards BACE1).
The first phase I/II studies were completed in 2012
(NCT01496170, NCT01537757) and demonstrated
tolerability with dose-proportional increases in
plasma and CSF exposure. Importantly CSF Aβ
was reported to be reduced by up to 92% (78). An
18-month phase 3 trial (EPOCH, NCT01739348)
enrolling 1,960 participants with mild to moderate
AD patients was then initiated in 2012 followed by
a second phase III trial (APECS, NCT01953601)
enrolling 1500 patients with earlier stages of the
disease (prodromal AD) in November 2013. The
EPOCH trial has finished recruitment and has an
estimated primary completion date in 2017 with a
final completion date in 2019 and the APECS trial
is recruiting with an estimated primary completion
date in 2019 and final study completion date in
2021. No preclinical or trial data has yet been
published for this molecule with most information
on its development being reported by the
developing drug company.
AZD3293 is an orally active, potent, highly
permeable (able to penetrated BBB) inhibitor of
BACE1 with unique slow off-rate kinetics that is
hoped to translate into a prolongation of any
observed effect beyond the turnover rate of Aβ. It
has demonstrated time- and dose-dependent
reductions of brain Aβ40 in mice, guinea pigs, and
dogs as well as other tissue types (79). Reductions
of up to 75% in CSF AB levels were reported in
initial phase I safety findings announced in
December 2013 and in at least ten other phase I
studies that further evaluated safety, tolerability,

or neutralize their toxicity based on the discovery of
the “artic mutation” in APP, which leads to a form
of Alzheimer's disease with particularly high levels
of Aβ protofibrils (73). A phase II, 18-month U.S.
trial is enrolling up to 800 people who either have
mild cognitive impairment due to AD, or who have
probable AD and whose diagnosis is confirmed by a
positive amyloid PET scan with the primary
outcome being a change in a composite of cognitive
tests (NCT01767311).
Another approach closely related to passive
immunotherapy of AD is IVIG (Gammagard)
administration. IVIG is a mixture of polyclonal
antibodies prepared from the blood plasma of
thousands of healthy young volunteers. IVIG binds
weakly to the monomeric form of Aβ and binds
strongly to neurotoxic oligomers and Aβ fibrils.
IVIG
also
has
immune-modulating
and
inflammatory effects which may potentially target
other AD mechanisms. A phase I trial in 8 patients
showed reduction in cognitive decline in 7 patients
that completed the trial and an improvement in
cognition six patients. Phase II and III trials in
patients with mild-to-moderate ensued but in 2012 a
phase III trial of 10% IVIG in 360 patients, while
generally safe and well-tolerated was terminated
due to lack of efficacy. Some positive results were
noted in subgroups, especially among APOE-e4
carriers and moderately impaired AD patients and
recruitment is ongoing for further phase III trials
(NCT01561053) in these populations (74, 75).
Recently, two planned phase III studies
(NCT01736579,
and
NCT01524887)
were
terminated, since the first Phase III study
(NCT00818662) failed to show efficacy and
confirmed the safety profile observed in Phase II
studies.
Secretase Inhibitors (γ and β)
The β-site APP cleaving enzymes 1 and 2 (BACE1
and BACE2) were initially identified as
transmembrane aspartyl proteases cleaving the
amyloid precursor protein (APP). BACE1 is a
major drug target for Alzheimer's disease because
BACE1-mediated cleavage of APP is the first step
in the generation of the pathogenic amyloid-β
peptides. However, BACE1 targeted drugdevelopment has been hindered, because the
enzyme has been found to have many substrates
with important physiological roles and initial nonselective inhibition of the enzyme was found to
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Table 2 - A summary of the clinical trials based on passive immunotherapy approaches (https://clinicaltrials.gov)
Clinical Trial
Start & End
Trial
outcome
Drug name
Number & Phase
date
population
Bapineuzumab was deemed to be relatively
NCT00397891 Bapineuzumab
2006 - 2010
80
safe and well tolerated as half of the ARIA
Phase I
cases were asymptomatic, and half suffered
NCT00112073 2005 - 2008
only transient symptoms with just one patient
Phase II
234
requiring steroid treatment. In phase III both
NCT00574132 trials failed to show an effect on cognitive or
Phase III
2007 - 2012
1331
functional primary outcomes or rate of brain
NCT00575055 volume loss.
Phase III
2007 - 2012
1122
NCT00667810 Phase III
2008 - 2013
901
NCT00676143 Phase III
2008 - 2012
1100
NCT00329082 -In phase II confirmed the antibody's safety
Solaneuzmab
19
Phase II
and tolerability.
2006 - 2008
- Phase III: ongoing
NCT00749216 2008 - 2009
Phase II
33
NCT01148498 2010 - 2012
Phase II
55
NCT00905372 2009 - 2012
1000
Phase III
EXPEDITION1
NCT00904683 2009 - 2012
1040
Phase III
EXPEDITION2
NCT01900665 2013 - 2020
2100
Phase III
EXPEDITION3
NCT01760005 Phase III
2012 - 2019
210
NCT02008357 Phase III
2014 - 2020
NCT02760602 1150
Phase III
2016 – 2021
2450

198

Special notes

Have reduced frequency of
adverse effects such as ARIA
compared to bapineuzumab.
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Table 2 Continued…
NCT00531804 Gantenerumab
Phase I
NCT01656525 Phase I
NCT02133937 Phase I
NCT01636531 Phase I
NCT01224106 Phase II/III
NCT02051608 Phase III
Crenezumab
(MABT5102A)

Aducanumab
(BIIB037)

NCT00997919 Phase I
NCT00736775 Phase I
NCT01343966 Phase II
NCT01397578 Phase II
NCT01723826 Phase II
NCT01998841 Phase II
NCT02670083 Phase III
NCT01397539 Phase I
NCT02434718 Phase I
NCT02782975 Phase I
NCT01677572 Phase I
NCT02484547 Phase III
NCT02477800 Phase III

2006 - 2010

60

2012 - 2014

28

2014 - 2014

31

2012 - 2012

120

2010 - 2019

799

2014 - 2019

389

2009 - 2010

22

2008 - 2010

56

2011 - 2014

448

2011 - 2014

91

2012 - 2017

360

2013 - 2020

300

2016 - 2021

750

2011 - 2013

53

2015 - 2016

20

2016 - 2016

40

2012 - 2019

197

2015 - 2022

1350

2015 - 2022

1350

It is generally safe and well-tolerated.
Phase III: ongoing

It is a fully human IgG1
antibody that preferentially
binds to aggregated Ab in the
brain and vasculature with
subnanomolar affinity and does
not alter plasma Aβ. The main
side effect was ARIA which
was as high as 14% but was
mostly asymptomatic and
associated with gantenerumab
dose and with the number of
ApoE 4 alleles a patient carried.
IgG4 monoclonal antibody
expected to reduce proinflammatory activity and limit
risk of vasogenic edema due to
reduced effector functions on
microglia

Statistically significant reduction on amyloid
plaque as well as a statistically significant
slowing of clinical impairment
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Human IgG1 monoclonal
antibody against a
conformational epitope found on
Aβ
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Table 2. Continued…
NCT00733642 Ponezumab (PFPhase I
04360365)
NCT00455000 Phase I
NCT01125631 Phase I
NCT01005862 Phase I
NCT00607308 Phase I
NCT00722046 Phase II
NCT00945672 Phase II
NCT01821118 Phase II
NCT01230853 BAN2401
Phase I
NCT02094729 Phase I
NCT01767311 Phase II
IVIG
(Gammagard)

NCT00299988 Phase II
NCT00812565 Phase II
NCT01300728 Phase II
NCT01561053 Phase II/III
NCT00818662 Phase III
NCT01736579 Phase III
NCT01524887 Phase III

Acceptable safety Profile
2008 - 2009

15

2007 - 2009

37

2010 - 2011

8

2010 - 2012

17

2008 - 2010

20

2008 - 2011

198

2009 - 2011

36

2013 - 2015

36

2010 - 2013

80

2013 - 2015

26

2012 - 2018

800

2006 - 2010

24

2009 - 2010

58

2011 - 2017

52

2012 - 2016

350

2008 - 2012

390

2012

6

2012

508

IgG2δA monoclonal antibody
that (unlike the other
monoclonal antibodies) binds
the free carboxyl terminal
amino acids 33-40 of the Aβ 140 peptide

Phase II studies failed to show any
significant therapeutic effect. It is no longer
pursued for AD treatment.

Well-tolerated, without incidents of ARIA

Humanized IgG1 monoclonal
antibody that binds selectively
to large, soluble Aβ protofibrils

A mixture of polyclonal
antibodies prepared from the
blood plasma of thousands of
healthy young volunteers.
IVIG binds weakly to the
monomeric form of Aβ and
binds strongly to neurotoxic
oligomers and Aβ fibrils.
Generally safe and well-tolerated; however,
efficacy was not observed.
Terminated, due to lack of efficiency
Terminated, due to lack of efficiency
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developed by Novartis that recently completed
phase II trials (March 2016 in 125 healthy patients;
NCT02576639). It is also being currently evaluated
in a phase II/III prevention study that will measure
delay to diagnosis of MCI or AD dementia in 1340
cognitively normal, homozygous ApoE4 carriers
aged 60 to 75. This study is somewhat unique in
that, half of the participants will be randomized to
either CNP250 or matching placebo, and the other
half to CAD106 or placebo (NCT02565511). Many
other BACE inhibitors have failed phase I/II trials
including LY2886721 terminated in phase II in
2013 after four cases of abnormal liver
biochemistry values, LY2811376 terminated in late
phase I due to damage to the pigment epithelium of
the eye found in simultaneous rat toxicology studies
and CTS21166, a small transition-state analog
inhibitor that was the first to pass a phase I clinical
trial in 2008 but whose development is not being
continued for unknown reasons. Various BACE
inhibitors including, GSK188909, have never gone
beyond pre-clinical stage of development.
γ-Secretases have also been evaluated in
clinical settings. While the amyloidogenic pathway
is initiated by BACE1, the γ-secretase enzyme is
responsible for the final stage of amyloidogenesis,
leading to the generation of Aβ1-40 and Aβ1-42
and is consequently a target for AD treatment.
However, substrate promiscuity promotes major
off-target secondary adverse effects and has
hindered development of γ -secretase inhibitors
early on. For instance, Notch, a major protein
responsible for regulating cell proliferation,
development,
differentiation,
and
cellular
communication, is one of the targets of γ-secretase.
Inhibition of Notch processing is responsible for
adverse events seen with early γ -secretase
inhibitors including severe gastrointestinal,
hematopoietic side effects, and neurodegeneration
and have been hampering the development of
clinically useful γ-secretase inhibitors so far.
Semagacestat (LY450139) is a γ-secretase
inhibitor that reduces Aβ40 and Aβ42 production
and was the first γ-secretase inhibitor to go into
phase III clinical trials. In preclinical animal
studies, semagacestat reduced both soluble Aβ and
amyloid plaque burden. Phase I evaluated
semagacestat in 27 healthy volunteers and showed
dose-dependent reduction in AB synthesis in the
CSF (84). Phase II trials, showed a greater number
of skin-related side effects in the treatment group

metabolism, and potential drug interactions of the
compound (80). A large phase II/III trial began
enrollment in September 2014, enrolling 2,202
patients with MCI due to AD or mild AD, to be
treated for 2 years and set to run for 5 years
(AMARANTH, NCT02245737). In June 2016, a
second phase III trial was initiated (DAYBREAKALZ, NCT02783573) with target enrollment of
1899 patients with mild AD only, also set to run 5
years with a 3-year treatment period.
JNJ-54861911 is another inhibitor of BACE1
also in phase II/III trials. It was initially optimized
through multiple steps by the Shionogi group in
Japan from hits with amino-dihydrothiazine or
modified versions of the cyclic isothiourea
warhead. JNJ-54861911 first began phase I testing
in 2013 and has undergone at least 11 phase I and
phase II trials. The inhibitor has been reported to
be safe and well-tolerated with dose-dependent
reductions in Aβ1-37, Aβ1-38, Aβ1-40, and Aβ1-42
with 90% reduction in AB seen with the highest
dose (81). In October 2015, a phase II/III study
began in asymptomatic people at risk of developing
Alzheimer's dementia (NCT02569398). This trial
will enroll 1,650 participants in Europe, Australia,
and Mexico. This trial will run until the year 2023.
A long-term safety and tolerability study of 100
patients from previous phase I /II trials is ongoing.
E2609 is another BACE inhibitor that is also in
development. It was initially developed through
several series of bicyclic aminodihydrothiazines
fused with unsaturated five- and six-membered
rings, and has shown significant reduction in CSF
and plasma levels of Aβ in non-human primates. At
least eight phase I trials have been completed
evaluating the safety and pharmacology of E2609 in
nearly 500 healthy volunteers and people with early
Alzheimer's disease including evaluation of the
compounds effects on the heart and interactions
with drugs commonly prescribed to the elderly. The
drug shows a reduction of Aβ levels in plasma and
a dose-dependent reduction of up to 80 percent in
CSF Aβ levels with headache and dizziness being
the most common adverse events although several
cases of orolabial herpes relapse were observed (82,
83). An 18-month phase II study in 700 people with
MCI due to AD or prodromal AD who have a
positive amyloid PET scan was initiated in
November 2014 and results are expected in January
2018 (NCT02322021).
CNP520 is another oral inhibitor of BACE
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Table 3 - A summary of the clinical trials based on passive β-secretase inhibitors (https://clinicaltrials.gov)
Drug name
Clinical Trial
Start & End date
Trial population
Outcome
Number & Phase
NCT01953601 ongoing
MK-8931
Phase III
2013 - 2021
1500
NCT02783573 2016 - 2021
1899 patients with mild
Ongoing
AZD3293
Phase III
AD
NCT02569398 Ongoing
JNJ-54861911
Phase II/III
2015 - 2023
1650

LY2886721

NCT02322021
Phase II
Phase II
NCT02565511
Phase II

2014 - 2018
November 2015August 2023
-

1340
-

LY2811376

Phase I

-

-

CTS21166

Phase I

-

-

Terminated in 2013 after
four cases of abnormal
liver biochemistry values
Terminated in late phase I
due to damage to the
pigment epithelium of rat
eye
Passed phase I

GSK188909

Preclinical

-

-

-

E2609
CNP520

Special note
No preclinical or trial data
has been published
Long term safety and
tolerability study is still
ongoing

Ongoing
700
Ongoing

The development is not
continued for unknown
reason(s)
Has never gone beyond
preclinical stage of
development

broad inhibition of 40-plus substrates of γ-secretase, particularly
Notch, which was previously not well-known. In particular, effects
on cognition were believed to be due to the accumulation of the
neurotoxic precursor of Aβ (the C-terminal fragment of APP or
CTFβ) resulting from the block of the γ-secretase cleavage activity
on APP (86).

including rash and lightening hair color. Despite these side effects,
two 21-month phase III trials, IDENTITY-1 and IDENTITY-2, were
initiated and enrolled a total of 3036 patients. Both trials were
terminated in April 2011 because of an increased risk of skin cancer
and infections in the treatment group. Moreover, cognition and
function not only did not improve but worsened in all treatment
groups (85). Failure of Semagacestat was believed to be due to the
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Some non-steroidal anti-inflammatory drugs
(NSAIDs) such as tarenflurbil, act as γ-secretase
modulators and shift the γ-secretase cutting point to
produce shorter nontoxic Aβ fragments. A phase II
trial with the NSAID tarenflurbil in mild to
moderate AD showed a significant improvement in
primary outcome of global functioning and
activities of daily living and a positive trend
towards improved cognition with a statistically
significant reduction in newly synthesized Aβ in
human volunteers. Phase III trials were completed
in 2008, and demonstrated an increased
deterioration in cognition and activities of daily
living compared to placebo-treated controls and it
was discontinued.
Compound CHF-5074, a molecule with a
formulation based on the structure of Rflurbiprofen, was being reported as a γ-secretase
modulator that affected Aβ- and other amyloidrelated outcomes. Subsequent preclinical studies
proposed other mechanisms of action, such as
restoring neurogenesis, reorganizing the astrocytic
cytoskeleton, reducing tau, rescuing synaptic
plasticity, or acting on microglia to counteract
inflammation (91). Three phase I clinical trials in
144 healthy young men reported CHF-5074 to be
safe and tolerable in these subjects; one notable side
effect was mild diarrhea. Three phase II trials were
conducted and the first reported trends toward
improved executive function, were reported for
carriers of the ApoE4 risk allele, but not noncarriers (92). It is unclear if the agent is undergoing
further development as the company awaits the
outcome of licensing negotiations.
There are many other γ-secretase inhibitors in
preclinical development. BMS-299897 is another γsecretase inhibitor that has been tested in animal
models. BMS-299897 blocked the increase in Aβ142 content and decreased Aβ1-40 levels
significantly in the Aβ25-35 mouse model of
Alzheimer's disease (93). MRK-560 is also another
γ-secretase inhibitor that is potent, orally
bioavailable, and can penetrate the brain. MRK-560
caused marked inhibition of both Aβx- 40 and Aβx42 in plasma, brain, and cerebrospinal fluid with
good correlation between plasma and brain and
plasma and CSF (94). Treatment of AD mice/rats
with the γ-secretase inhibitor DAPT has also been
studied and resulted in decreased Aβ levels in
plasma and cerebrospinal fluid (CSF) (95).

Avagacestat is another γ-secretase inhibitor
which was discontinued as a result of a lack of
efficacy
(NCT00810147,
NCT00890890,
NCT00810147, and NCT01079819). Avagacestat
was reported to selectively block processing of the
enzyme's APP substrate with 137-fold selectivity
for APP over Notch in cell culture, and to reduce
CSF Aβ levels without causing Notch-related
toxicity in animals (87, 88). About a dozen phase I
trials evaluated the safety and pharmacology of
avagacestat in healthy volunteers and people with
Alzheimer's disease. In particular, drug-interaction
studies were conducted with cholinesterase
inhibitors, blood thinners, and a range of other
drugs commonly used in aging populations,
including topical antibiotics and disinfectants. In
2009, two Phase 2 trials were started, of which one
was completed, and the other was terminated. In the
first multinational trial with 209 people with mild to
moderate Alzheimer's disease many patients
dropped out due to gastrointestinal and
dermatological side effects and non-melanoma skin
cancers were also seen. The trial generated a dosedependent pharmacodynamics model for the effects
on CSF biomarkers in some patients, but at the two
higher doses cognition trended toward a worsening
compared with placebo (89). ARIA also occurred in
some patients. In the second phase II trial,
avagescat was evaluated in the prodromal
population and showed similar results and the trial
was terminated in 2012.
Begacestat (GSI-953) was another γ-secretase
inhibitor
that
went
through
pre-clinical
development was, which was 16-times more
selective for the inhibition of APP cleavage over
Notch. However, phase I trials (NCT00959881,
NCT00547560) in healthy human volunteers only
affected the plasma concentration of Aβ and not its
CSF concentration and development was halted
(90). Another compound, NIC5-15 (pinitol) is a
naturally occurring cyclic sugar alcohol found in
soy and several other plants and fruits. It is also
believed to modulate γ-secretase that is selective for
APP. A Phase 2a and 2b trial were completed in 15
and 30 people respectively in 2013 and the
compound was reported to indicate good
tolerability, as well as stabilization of cognition as
measured by the ADAS-Cog (NCT01928420). It is
unclear if this is being pursued for further
development.
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Table 4 - A summary of the clinical trials based on passive γ-secretase inhibitors (https://clinicaltrials.gov)
Clinical Trial
Start & End
Trial
Drug name
Outcome
Number & Phase
date
population
NCT00762411 Terminated in April 2011
Semagacestat
Phase III
2008 - 2011
1111
Increased risk of skin cancer and
(LY450139)
NCT00594568 infections
Phase III
2008 - 2011
1537
Cognition and function not only did
NCT01035138 not improve but worsened in all
Phase III
2009 - 2011
180
treatment groups
NCT00810147 2009 - 2010
- GI and dermatological side effects
Avagacestat
Phase II
209
and non-melanoma skin cancers
NCT00890890 2009 - 2013
- Terminated, due to lack of efficacy
Phase II
263
and similar side effects
NCT00547560 Only affected the plasma
Begacestat (GSIPhase I
2007 - 2009
49
concentration of Aβ and not its CSF
953)
NCT00959881 concentration
Phase I
2009 - 2009
47
Its development was halted
NCT00470418 Indicated good tolerability and
NIC5-15
Phase IIa
2007 - 2010
15
stabilization of cognition as measured
NCT01928420 by the ADAS-Cog
Phase IIb
2007 - 2014
30
NCT00105547 Increased deterioration in cognition
Tarenflurbil
Phase III
2005 - 2008
1600
and activities – Discontinued
CHF-5074

NCT00954252-Phase
I
NCT01203384-Phase
I
NCT01258452-Phase
I
NCT01303744-Phase
II
NCT01421056-Phase
II
NCT01602393-Phase
II

safe and tolerable – Mild diarrhea
2009 - 2010

84

2010 - 2010

48

2011 - 2011

12

2011 - 2012

96

2011 - 2012

74

2012 - 2013

51

Improved executive function for
carriers of the ApoE4 risk allele but
not non-carriers
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Special note
Reduces Aβ40 and Aβ42
production
First γ-secretase inhibitor to go
into phase III clinical trials

Selectively blocks processing of
the enzyme's APP substrate
with 137-fold selectivity for
APP over Notch
16-times more selective for the
inhibition of APP cleavage over
Notch
Naturally occurring cyclic sugar
alcohol found in soy and
several other plants and fruits
NSAID
It is not clear if it is undergoing
further development
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BMS-241027 restored microtubule dynamics to
baseline levels with beneficial effects seen on
performance in the Morris water maze deficits, tau
pathology, and neurodegeneration (100). However,
BMS 241027 has undergone phase I trials in 40
patients which were completed in October 2013
(NCT01492374) and the agent has not been pursued
further in AD development. TPI-287 is another
tubulin-binding and microtubule stabilizing agent
that is also a synthetic derivative of the taxane
drugs used in oncology for various brain tumors. It
is being tested in phase I trials in 33 patients in
November 2013 that is currently recruiting AD
patients for phase I study (NCT01966666). The
study is set to run until March 2017. A phase I
study
in another tauopathy, corticobasal
degeneration (CBD), or progressive supranuclear
palsy (PSP) was also initiated in 2014
(NCT02133846).
Similar to beta-amyloid, immunotherapy
directed against the tau protein is also a target for
development. Passive immunization with specific
monoclonal
antibodies
directed
against
phosphorylated tau is being studied and are in
various stages of pre-clinical testing (101, 102).
Because active immunization against tau is much
further along in development. Active immunization
using human, recombinant, full-size, nonphosphorylated tau protein has been associated with
neurotoxicity in animal models, this has led to the
development of modified peptides to actively
immunize against Tau. AADvac1 is the first
vaccine to undergo clinical trials for active
immunization against tau in AD. AADvac1 is
directed again shortened, non-native tau which is
susceptible to aggregation and is targeted against
amino acids 294 to 305 of the tau sequence derived
from the regulatory domain driving the
oligomerization of tau. An extra N-terminal
cysteine residue is added to obtain attachment of the
peptide to the keyhole limpet hemocyanin and
coupled to using aluminum hydroxide carrier (103).
Phase 1 trials in 30 patients with mild-to-moderate
AD were conducted from 2013-2015. Two patients
reportedly withdrew due to adverse events,
including a viral infection which was followed by a
seizure. Safety and tolerability however was
deemed such that a 24-month phase II trial in
patients with mild-to-moderate AD was initiated in
December 2015 with an expected completion date
2018. It intends to enroll 185 patients with mild AD

Tau Targeted Therapies
Aggregates of abnormally hyperphosphorylated tau
are the components of neurofibrillary tangles, the
hallmark lesion in AD other than beta-amyloid. Tau
has more recently been emerging as potentially an
equally important biological target for innovative
AD therapies. Potential tau therapies include
inhibition of tau phosphorylation, microtubule
stabilization, prevention of tau oligomerization, and
enhancement of tau degradation as well as tau
immunotherapy. Most agents directed against the
tau protein are still in preclinical tests, with only a
handful having reached clinical trials.
The tau therapy furthest along in development
is TRX0237 also known as leucomethylthioninium
(LMTX). This compound is a derivative of a wellknown Methylene Blue dye, i.e. methylthioninium
chloride but was improved for enhanced
bioavailability and tolerability (96). The purported
action of both of these compounds is to act as tau
aggregation inhibitors by not only inhibiting the
formation of new oligomers, but more importantly
to release soluble tau from oligomers and paired
helical filaments in a monomeric form which is
susceptible to proteases (97). In a large 12-month
phase II study in 321 subjects, MTC was found to
stabilize the progression of AD over 50 weeks in
both mild and moderate AD (98). The more stable,
reduced version of methylthioninium, LMTX, was
tested in two parallel phase III studies in AD in 250
centers in 22 countries world-wide enrolling 891
patients
with
mild-to-moderate
AD
(NCT01689246) completed at the end of 2015 and
in 800 patients with mild AD (NCT01689233)
completed in June 2016. Of note, these therapies are
also being tested in other phase III trials for another
tauopathy,
frontotemporal
dementia
(NCT01626378). The clinical trials based on tau
targeted therapies are summarized in Table 5.
Because tau is a component of microtubules
and hyperphosphorylation of tau results in
microtubule
destabilization
and
resulting
cytoskeleton degeneration, other agents of interest
in AD are agents with microtubule stabilizing
effects (99). Agents that have been tested in phase I
clinical trials include epothilone D (BMS-241027)
and TPI-287. Epothilone D (BMS-241027) is a
small molecule taxane drug that has been
previously studied in oncology and is capable of
penetrating the blood–brain barrier and normalizing
tau binding at low doses. In tau transgenic animals,
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phosphorylation. Nasal insulin is being explored
specifically because this particular route of
administration can effectively deliver insulin
directly into the brain without the unwanted effect
of increasing systemic insulin levels. Multiple small
pilot studies have been conducted with nasal
insulin. These studies have reported benefit in
cognition including improved verbal memory and
attention, although these studies are small and
inherently methodologically flawed (109-111).
Differential effects of insulin by ApoE genotype
has also been proposed (112). Phase II/III clinical
trials which were initiated in 2013 are currently
ongoing for Humulin R in patients with the mild
form of AD and is expected to be completed in
2017 (NCT01767909).
The efficacy of the human insulin analogue
glulisine (Apidra ®) is also being evaluated in
patients with AD. A phase II, single center,
randomized, double-blind, placebo-controlled of
intranasal glulisine enrolling 90 patients with mild
cognitive impairment and probable mild AD was
initiated in August 2015 and is expected to be
completed in September 2017 (NCT02503501).
Prior phase I studies showed that glulisine was well
tolerated but failed to have an acute impact on
cognition in ApoE4 carriers with AD (113).
However, these studies were not powered to show
effect.

(ADAMANT, NCT02579252).
Another potential AD therapy in development
which actively immunizes against the tau protein is
the liposomal-based vaccine ACI-35. The vaccine
contains 16 copies of a synthetic tau fragment that
is phosphorylated at the protein’s pathological
phosphorylation residues S396 and S404 and is
anchored into a lipid bilayer. It uses the adjuvant
MPLA (104). In pre-clinical studies it rapidly
generated high titers of polyclonal IgG antibodies
specifically directed against phosphorylated tau,
rather than non-phosphorylated tau, reducing
soluble tau as well as insoluble, aggregated tau in
brain extracts (105). In December 2013, a phase 1b
multicenter, double-blind, randomized, placebocontrolled study of the safety, tolerability and
immunogenicity of ACI-35 was initiated recruiting
24 patients. The trial has been completed and
results are pending (ISRCTN13033912). As
hyperphosphorylated tau protein is prone to
aggregation leading to loss of cytoskeletal
microtubule-stabilizing properties and degeneration
of neurons, potential compounds preventing tau
phosphorylation are also of interest. The most
important protein kinase involved in tau
phosphorylation is glycogen synthase kinase 3 beta
(GSK-3β) whose enzyme activity is also reportedly
up-regulated by neurotoxic Aβ. Multiple GSK-3β
inhibitors are under development.
Tideglusib (NP031112, NP-12) is an orally
available
small
molecule
drug
of
the
thiadiazolidinone class. It acts as an irreversible
GSK-3β inhibitor that has been shown to reverse
amyloid in brain and prevent cell loss and reduce
spatial memory deficits in preclinical studies (106,
107). Phase IIa studies in 30 patients reported good
tolerability except for a transient increase in serum
transaminase levels (108). However, the follow-up
phase IIb trial was aborted in 201 of 306 patients
with
mild-to-moderate
AD
(ARGO,
NCT01350362), because primary endpoints were
not met. The drug continues to be evaluated in
progressive supranuclear palsy which is considered
a pure tauopathy.
Insulin is also being studied in the treatment of
AD. Insulin has been proposed to play a role in
multiple AD disease pathways including against Aβ
toxicity, neuro-inflammation, and tau pathology.
The role of insulin in tau pathology is believed to be
due to its effects on the decreasing the activity of
GSK-3, thereby leading to inhibition of tau

Neurotransmitter-based therapies
Muscarinic agonists
The muscarinic acetylcholine receptors are G
protein coupled receptors which comprise 5
subtypes, M1 - M5, that play an important role in
attention, the sleep-wake cycle and memory (114116). M1 in particular, plays a pivotal role in
cognition and memory and are distributed
throughout the cortex and hippocampus. M1
muscarinic receptors are believed to play an
important role in the regulation of secretase
activities and synthesis of Aβ peptide, and
subsequent tau hyperphosphorylation and cognitive
dysfunction (117, 118). M1 receptor activation
activates α-secretase and leads to increased
secretion of sAPPa and subsequent inhibition αsecretase which then decreases production of Aβ.
M1 receptor activation is also believed to inhibit
oxidative stress which leads to cell death. As such
M1 receptor agonists have been targets for drug
development in AD.
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Table 5 - A summary of the clinical trials based on passive γ-secretase inhibitors (https://clinicaltrials.gov)
Drug

Clinical Trial
Number & Phase

Start & End
Date

Trial
Population

2012 - 2016

800

2013 - 2015

891

NCT01689233 phase III
NCT01689246 Phase III
NCT01492374 Phase I
NCT01966666 phase I

2012 - 2013

40

2013 - 2017

33

Active immunization
(AADvac1)

NCT02579252 phase II

2016 - 2019

185

Tideglusib
(NPO31112, NP-12)

NCT00948259 Phase I/II
NCT01350362 Phase II
NCT02586935 Phase II

2008 - 2009

30

2011 - 2012

306

2015 - 2017

90

2013 - 2017

240

2011-2013

12

2015-2017

90

Leucomethylthioninium
(LMTX)
(TRX0237)
Epothilone D (BMS241027)
TPI-287

Insulin
Glulisine (human insulin
analog)

NCT01767909 Phase II/III
NCT01436045 Phase II
NCT02503501 Phase II

Outcome

Special note
Tau aggregation inhibitor

Not being pursued for
AD

A small molecule taxane drug capable of
normalizing tau binding
Synthetic derivative of taxane drugs
Active immunization against tau protein

Good tolerability (with
transient increase in
serum transaminase
- Aborted in 201 of 306
patients

Irreversible GSK-3b inhibitor
transient increase in serum transaminase
levels

Humulin® R U-100

Effects on the decreasing the activity of
GSK-3
Failed to have an acute impact on cognition
in ApoE4 carriers in phase I

muscarinic receptor agonist evaluated in patients with probable AD.
In phase II studies in 343 patients a significant treatment effect was
seen in cognition, global function, and behavioral symptoms but
almost 50% of patients in the high-dose arm discontinued treatment
due to adverse events which were primarily gastrointestinal in nature

There are three types of M1 mAChR-targeting drugs currently in
development, including orthosteric agonists, allosteric agonists, and
M1 positive allosteric modulators (M1 PAM).
The first generation of M1 receptor agonists bind to an
orthosteric ACh-binding site. Xanomeline was an M1/M4 selective
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in animal models, while also reportedly decreasing
BACE1, GSK3β activity, neuro-inflammation,
soluble and insoluble Aβ40, Aβ42, plaques and tau
pathologies (125). While AF710B is believed to
have much promise as a potential therapy in AD, it
has not yet entered clinical phases of development.
Currently, the only M1 receptor agonist that is in
clinical trials is HTL9936 which completed the
phase I trials in 2014 (NCT02291783).
The M1 PAMs group cannot activate receptors
directly, but can change the receptor conformation
after binding, which then leads to a change in the
ligand-binding and functional properties of the M1
receptors. These muscarinic agents then have a
novel and highly targeted mode of action and act
only on a single muscarinic receptor subtype which
is functioning sub-optimally and therefore be of use
therapeutically in the early stages of AD. Therefore,
M1 PAMs are active in the presence of the
endogenous neurotransmitter Ach and inactive in its
absence, which theoretically aids in the reduction of
side effects. Brucine was one of the first PAMs
identified and was capable of selectively enhancing
the effects of acetylcholine at M1 receptors by an
allosteric mechanism (126). There are several other
PAMs that act on M1, such as VU0029767 and
VU0090157 which were previously in preclinical
development (127). ML169 is a M1 PAM which
has more recently been in preclinical developed
(128). No M1 PAMs are currently in clinical trials.

believed to be due from non-selective binding of
M1 and M2 (119). The clinical studies pursued
based on different neurotransmitter-based therapies
are summarized in Table 6. Other M1 muscarinic
agonists include AF102B, AF150(S), and AF267B
which are highly bioavailable, blood-brain barrier
penetrant, partial agonists that elevate the nonamyloidogenic amyloid precursor protein in vitro,
decrease beta-amyloid levels in vitro and in vivo,
and can inhibit beta-amyloid and oxidative-stressinduced cell death in cell lines. These drugs also
restored cognitive impairments in several animal
models for AD (120). AF102B failed in clinical
trials due to gastrointestinal side effects, confusion,
and diaphoresis and AF267B failed to show
efficacy in clinical trials and was discontinued.
LY593093 is a newer M1AChR orthosteric agonist
that demonstrates modest to no activity at the other
muscarinic subtypes and displays efficacy in the in
vivo models of cognition (121). However, it is
unclear if it is being pursued for clinical trials.
Allosteric compounds bind to allosteric binding
sites and have a better selectivity for the M1
subtypes than do the previously described
orthosteric agonists. Allosteric compounds can be
classified into regular agonists and M1-positive
allosteric modulators (PAMs). Allosteric agonists
of the M1 receptor activate the receptor at a site
distinct from the orthosteric ACh site which
contributes to selectivity for M1 receptors. Early
allosteric agonists (e.g., AC-42) could not activate
M1 receptors in systems such as brain slices and
had poor solubility in a physiologic buffer system,
which prevented the in vivo use. Newer allosteric
agonists, such as TBPB, were developed to be
highly selective for M1, blood brain barrier
penetrant, and also activate NMDA in hippocampal
pyramidal neurons. TBPB promotes the processing
of APP towards the non- amyloidogenic pathway,
decreases Aβ production in vitro, and has been
shown to improve cognition in animal models
(122). 77-LH-28-1 is another potent, selective and
CNS penetrant allosteric M1 agonist which was a
structural analog of AC-42 that was reported to
improve cognition in animal models (123) as did
AC-260584 (124). However, it is unclear if any of
these agents are being pursued for clinical
development. A unique agent is AF710B, which is a
highly potent and selective allosteric M1 muscarinic
agonist while also being a σ1 receptor agonist.
AF710B was a potent and safe cognitive enhancer

Nicotinic agonists
The role of nicotinic receptors in AD is less clear
than muscarinic agonists, but it is known that
nicotinic acetylcholine receptors (nAChRs) play
diverse roles in cognition, memory, and neuroprotection (129). Unlike muscarinic receptors,
which are G-protein coupled receptors, nicotinic
receptors are ligand-gated ion channels. The
therapeutic nicotine effect is secondary to increased
release of ACh through the activation of nAChRs
and the subsequent activation of M1 receptors by
acetylcholine (130). Studies have shown that α7nicotinic agonists attenuate Aβ mediated toxicity
but may increase phosphorylation of tau (131, 132).
Many novel ligands for α7-nicotinic AChR have
reached phase III development.
EVP-6124 (also known as encenicline
hydrochloride) is a novel selective α7-nAChR
partial agonist that was evaluated for the treatment
of cognitive deficits in both schizophrenia and AD
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that very recently failed phase III trials. In AD, an
initial ascending-dose phase I/II study showed
smaller doses of 0.1 to 1 mg/day of EVP-6124 (0.1
to 1mg/day) to be safe and well-tolerated in 49
people with mild to moderate AD for 28 days.
Secondary efficacy endpoints at that time suggested
that EVP-6124 could improve attention, verbal
fluency, and executive function, when given in
conjunction with acetylcholinesterase inhibitors
(133).
As such, a 24-week phase II trial
(NCT01073228) was conducted in 409 people using
higher doses in mild to moderate AD patients and
met most of its primary and secondary endpoints,
including cognitive measures (134). This led to the
initiation of two international phase II trials
enrolling a total of 958 patients with mild to
moderate AD who were already taking an
acetylcholinesterase inhibitor in October 2013
(NCT01969123 and NCT01969136). The trial
compared two fixed, undisclosed add-on doses of
EVP-6124 to placebo and was set to run through
2016 with results being available in 2017.
However, in September 2015, the FDA placed a
hold on these trials due to reports of rare but serious
gastrointestinal side effects. Phase III studies in
schizophrenia continued as these patients did not
seem to suffer from the same gastrointestinal side
effects, but after the drug missed its co-primary
endpoints in the schizophrenia phase trials, the
development of this compound was discontinued.
ABT-126, also known as nelonicline, is another
α7-nAChR allosteric modulator that has undergone
extensive clinical development. It is similarly being
tested in schizophrenia and Alzheimer's disease.
Phase 1/2 research for ABT-126 began in 2009.
The compound was compared to both placebo and
to donepezil and preliminary data was reported to
have shown good tolerability for ABT-126, with
side effects similar to donepezil (135). In 2012, two
24-week Phase 2b trials in 400 patients each,
compared ABT-126 added on to donepezil to
placebo, and compared ABT-126 monotherapy to
placebo (NCT01549834). However, although ABT126 was generally well tolerated with the most
common
adverse
events
were
agitation,
constipation, diarrhea, fall, and headache, ABT-126
did not demonstrate significant improvement in the
primary efficacy endpoint and a treatment effect
was not observed for any secondary efficacy
measures of cognition, function, or global
improvement (136).

Serotonin antagonists
Serotonin indirectly affects neurodegenerative
processes. 5-HT6 serotonin receptors in humans are
present in areas responsible for memory and
cognitive function. Blockade of 5-HT6 receptors
increases synaptic acetylcholine release, improving
cholinergic transmission and enhances memory and
cognition (137-139). Antagonists of 5-HT6 are
under development for AD. Idalopirdine (Lu
AE58054) is a 5-HT6 that has been reported to be
highly selective, aside from some affinity for
adrenergic receptors (140). Lu AE58054 has
successfully undergone phase I trials in healthy
volunteers. Since the results of preclinical tests
suggested that the use of 5-HT6 antagonists in
combination with cholinesterase inhibitors may
increase the beneficial effects of both drugs on
cognition, a phase II study with idalopirdine and
donepezil was carried out among 278 patients with
moderate AD. Results indicated improvement of
cognitive function, although in 14 people taking
idalopirdine
transient
increases
in
liver
transaminase levels were observed (141). Two
Phase III studies evaluating the efficacy of
LuAE58054 were initiated in 2013 enrolling 932
patients (STARSHINE, NCT01955161) and 858
patients (STARBEAM, NCT02006641) with mildto-moderate AD also on donepezil therapy. These
studies have completed recruitment and are
expected to be completed in 2017. An open-label
extension phase III study for these trials were
initiated in 2014 and this trial will also evaluate
psychiatric endpoints (NCT02079246).
Another 5-HT6 receptor antagonist, SB-742457
also known as RVT-101 has also reached phase III
trials. In animals, SB-742457 has been reported to
not only have beneficial effects in AD models, but
also in age-related cognitive decline in rats (142).
SB-742457 was also studied in patients with or
without donepezil in phase II clinical trials
completed in 2011 (NCT00710684). In the studies
evaluating SB-742457 alone, no benefit was seen in
cognition, but a significant improvement in global
function was seen in those studies that evaluated
patients also receiving donepezil (143). A phase III
trial was initiated in 2015 enrolling 1150 patients
with mild-to-moderate AD who are also stable on
donepezil (MINDSET; NCT02585934). This trial is
expected to be complete in 2017. Also, a phase II
trial in patients with dementia with lewy body
disease was initiated in January 2016 (HEADWAY-
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no improvements were observed in any other
domains of cognition or other secondary endpoints
indicating that H3 agonists at most, have modest
and selective effects on cognitive function in
patients with mild-to-moderate AD (148). Finally,
dimebon is an antihistamine that has been used in
Russia since the 1980s to treat allergic rhinitis,
which made it to phase III trials in AD. Dimebon is
a pleiotropic drug with activities beyond blocking
H1 histamine receptors. A mechanism of action for
cognitive benefit has never been conclusively
established; however, a broad spectrum of effects
has been proposed including modulation of NMDA
glutamate receptors, α-adrenergic receptors, and
serotonergic or dopaminergic receptors (149).
Phase I and II trials of a total of 197 Alzheimer's
patients in Russia showed Dimebon was safe, well
tolerated, and significantly improved the clinical
course of patients with mild-to-moderate AD (150).
This was then followed by two Phase III trials
initiated in 2009 in patients with mild to moderate
AD conducted in the Americas, Europe, Australia,
and New Zealand, but neither Phase III study
detected change in any primary or secondary
outcome (NCT00838110, NCT00675623, and
NCT00829374; CONNECTION).

DLB; NCT02669433). SUVN-502 is a selective
antagonist of the 5-HT6 serotonin receptor that is
currently recruiting for phase II human trials. In
September 2015, a phase 2a proof-of-concept trial
began enrolling 537 patients with probable
Alzheimer's disease to compare SUVN-502 to
placebo, all given in addition to donepezil. The
treatment period of the trial is to last 26 weeks and
the study is expected to be complete in June 2017
(NCT02580305).
Other 5-HT receptor subtypes have been
studied in AD but have failed to show benefit. For
instance, lecozotan, a 5-HT1a receptor antagonist
which was shown to produce significant
improvement in task performance efficiency and
reverse learning deficits in animals (144), went as
far as phase II/III studies (NCT00277810);
however, it was not pursued further for AD
development. Another orally active 5-HT1a
receptor antagonist that was triggering some interest
was called xaliproden, which was reported to
counteract Aβ-induced neuronal toxicity and
memory deficits in rats (145). However, two 18month Phase 3 trials in mild-to-moderate
Alzheimer's disease, one enrolling 1,455 patients,
the other 1,306 completed in 2007, found no
beneficial therapeutic effect (NCT00104013 and
NCT00103649).

Neurotrophic and Hematopoietic Growth
Factors
Brain-Derived Neurotrophic Factor
Brain-derived neurotrophic factor (BDNF) is a
member of neurotrophins family, which are formed
through
post-translational
modifications
to
proneurotrophins. It has been suggested that BDNF
could play an important role in AD, due to
promotion of neuron survival and synaptic
regulation via TrkB receptor and PIEK/Akt
signaling pathway (151). It has been linked to
learning and memory, due to its role in axonal
sprouting, dendritic proliferation, and neuronal
differentiation (152). Loss of BDNF function has
been reported in neurodegenerative and psychiatric
diseases (153, 154). Genetic structure and
intracellular mechanisms of BDNF was recently
reviewed by Adachi et al (155).
Multiple studies have revealed a drop in BDNF
levels in AD patients (156-159), while other reports
indicate an increase in BNDF expression compared
to control (160), which could be a compensatory
repair mechanism during early stages of AD.

Histamine antagonists
Histamine H3 receptors (both auto- and heteroreceptors) are also present in large amounts in the
prefrontal cortex, hippocampus, and hypothalamus
which are important for memory and cognition.
Blockage of the pre-synaptic H3 receptor leads to
increased release of acetylcholine, dopamine,
GABA, noradrenaline and histamine into the
synaptic cleft, indirectly improving cholinergic
neurotransmission (146). ABT-288, a competitive
selective H3 receptor antagonist was a
histaminergic antagonist that reached phase II trials
in 242 patients with mild to moderate AD
completed in 2011. Unfortunately, the trial was
terminated early, as no statistical changes in
cognitive function was found and because futility
criteria were met (147). GSK239512, another H3
antagonist with an acceptable safety profile,
underwent phase II trials in 196 patients with mild
or moderate AD (NCT01009255). In this 16-week,
double-blind, randomized, parallel group study,
GSK239512 improved Episodic Memory; however,
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Table 6 - A summary of the clinical trials based on neurotransmitter-based therapies (https://clinicaltrials.gov)
Drug
HTL9936

EVP-6124

ABT-126
nelonicline

Idalopirdine
(Lu AE58054)

Clinical Trial
Number & Phase
NCT02291783 Phase I
NCT00766363 Phase I
NCT01073228 Phase II
NCT01969123 Phase III
NCT01969136 Phase III
NCT02327182 Phase III
NCT02004392 Phase III
NCT00948909 Phase II
NCT01549834 Phase II
NCT01527916 Phase II
NCT01676935 Phase II
NCT01690195 Phase II
NCT01019421 Phase II
NCT01955161 Phase III
NCT02006641 Phase III
NCT02079246 Phase III
NCT02006654 Phase III

Start & End
Date

Trial
Population

2013 - 2014

108

2008 - 2009

49

2010 - 2012

409

2013 - 2017

474

- Well-tolerated - improved
attention, verbal fluency
- Met most of primary and
secondary endpoints
- Terminated

2013 - 2017

403

- Terminated

2014 - 2015

117

- Terminated

2014 - 2017

348

- Terminated

2009 - 2010

274

- Good tolerability

2012 - 2013

434

- No significant improvement

2012 - 2013

438

- No significant improvement

2012 - 2014

349

- Terminated

2012 - 2014

343

- Terminated

2009 - 2011

278

- Improvement of cognitive function
(with donepezil)

2013 - 2017

932

2014 - 2017

858

2014 - 2017

1770

2014 - 2017

734

Outcome

Special Note
M1 receptor agonist
α7 nAChR partial agonist
for the treatment of cognitive deficits in both
schizophrenia and AD given in conjunction
with acetylcholinesterase inhibitors

α7-nAChR allosteric modulator
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Highly selective for 5-HT6, aside from some
affinity for adrenergic receptors
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Table 6. Continued…
NCT00710684 phase II
SB 742457
NCT02585934 (RVT-101)
Phase III
NCT02580305 SUVN-502
Phase II
NCT00277810 lecozotan
phase II/III
NCT00104013 Phase III
xaliproden
NCT00103649 phase III
NCT01018875 ABT-288
Phase II
NCT01009255 phase II
GSK239512

Dimebon

NCT00838110 Phase III
NCT00675623 Phase III
NCT00829374 Phase III

- No benefit alone; significant
improvement with donepezil

2008 – 2011

684

2015 - 2017

1150

2015 - 2017

537

2006 - 2008

250

Not pursued further for AD
development

2003 - 2007

1455

- No treatment effect

2003 - 2007

1306

2009 - 2011
2009 - 2010

242
196

2009 - 2010

742

- No treatment effect
- Terminated; no change in
cognitive function
Modest and selective effects on
cognitive function in patients with
mild-to-moderate AD
No change in any primary or
secondary outcome

2008 - 2009

598

2009 - 2011

1003

Beneficial effects in AD models but also in
age-related cognitive decline in animals

With donepezil
5-HT1a receptor antagonist
5-HT1a receptor antagonist reported to
counteract Aβ-induced neuronal toxicity and
memory deficits in rats
Competitive selective H3 receptor antagonist
H3 antagonist
Antihistamine used in Russia since the 1980s
to treat allergic rhinitis

associated with an increase in BDNF levels (164). Antidepressants
have also reported to increase BDNF levels in AD patients (165).
However, a recent clinical trial showed no significant effect of
donepezil treatment on BDNF levels (166), while a 2009 clinical trial
have indicated an increase in BDNF levels in lithium-treated patients
with early AD (167). BDNF levels have been analyzed as a biomarker
in other clinical trials conducted on AD treatment, especially in trials on
the effect of physical activity and exercise on AD (168-170). Beneficial
effect of BDNF in several mouse models of AD has also been reported.
Delivering the BDNF gene in transgenic mice that constantly produces
BDNF, has interfered with loss of synapses, and enhanced the cognitive
function, without co-interacting with β-amyloid (171).

Overall, it has been hypothesized that activating BDNF
intracellular signaling could be a promising strategy in AD treatment
(151). In 2013, Xu et al. reported a positive effect of a variety of
flavonoids on expression levels of BDNF (161). Recently, DiazGerevini et al. reported a link between flavonoid resveratrol and
enhancement of synthesis and mechanism of BDNF (162). Another
possible pharmacological intervention that could positively affect
BDNF levels is curcumin. Curcumin has been extensively studied for
anticancer, antioxidant, and anti-inflammatory properties (163).
However, it has been suggested that curcumin could also inhibit
DNA methyltransferase, histone acetyltransferase and histone
deacetylase, and modulate miRNA in hippocampus, which are
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mice model of AD (186). Maybe even more
interestingly, this study has also demonstrated an
increase in BDNF expression level, which might
indicate a link between the two growth factors in
their protective role against neuron degeneration.

Nerve Growth Factor
Another member of neurotrophic factors is nerve
growth factor (NGF), which is a glycoprotein
synthesized from the inactive form, pro-NGF (172),
and exerts its trophic effect via TrkA and P57
receptors (173). NGF plays an important role in
maintaining neuronal proliferation and growth of
neurons by interacting with other growth factors,
and maintenance of cholinergic neurons and
memory-related parts of CNS (e.g., hippocampus)
(174). A drop in NGF levels with aging has been
reported in many animal models (175-177), which
could be an indication of the beneficial effects of
NGF in AD patients. However, recent studies have
not revealed a significant difference in blood, CSF,
and brain levels of NGF in AD patients compared
to healthy subjects (178). In a small phase I clinical
study (8 patients) reported in 2005, transfected
fibroblasts with permanent expression of NGF were
implanted in the forebrain of the patients, and
significant increase in neuronal activity was
reported (179). Also, a more recent Phase I clinical
study with ex vivo gene delivery to AD patients
demonstrated enhanced cerebral metabolism and
cognitive function without significant adverse
effects (180). Positron emission tomographic (PET)
scans confirmed the inhibition of the metabolic
decline expected in AD patients.

Granulocyte–Colony Stimulating Factor
A potent growth factor with a stimulating effect on
myeloid cells, granulocyte-colony stimulating
factor (G-CSF), is also reported to inhibit apoptosis
and induce neuronal differentiation in vitro (187). A
decrease in G-CSF blood levels in early AD
patients has been reported by Laske et al, with no
data available for the CSF or brain level of this
growth factor (188). Tsai et al. have reported a
significant cognitive improvement in transgenic
mice models of AD after 5 days of subcutaneous
injection of G-CSF (189). They also reported that
G-CSF administration induced neurogenesis around
Aβ aggregates in these acute and chronic animal
models of Aβ-driven AD. In 2012, a pilot clinical
study in 8 patients with mild to moderate stages of
AD did not show a serious adverse effect for five
days of subcutaneous G-CSF administration, but
did provide evidence for positive changes in
hippocampal-dependent cognitive tasks (190).
Stem Cell Factor
Stem cell factor (SCF) is a hematopoietin expressed
in CNS that enhances neurogenesis (191). It might
also have a role in survival and migration of neural
stem cells (192). Along with G-CSF it helps bone
marrow-derived progenitor cells differentiate to
microglial cells or neuronal stem cells (192). This
suggests a protective role towards neurons, which
might be exerted via PI3K/Akt or MEK/ERK
pathways (193). A decrease in plasma and
cerebrovascular fluid levels of SCF has been
reported in AD patients (194). It has also been
shown that a higher SCF level correlates with
slower deterioration of cognition in AD patients
(195).

Glial-Derived Neurotrophic Factor
Originally isolated from medium of a rat glioma
cell line, glial-derived neurotrophic factor (GDNF)
is another important growth factor, especially for
survival and maintenance of dopaminergic neurons
in midbrain (181). GDNF also seems to play a
major role in enhancing the blood brain barrier.
However, the neurotrophic effect of GDNF is only
observed in the presence of transforming growth
factor β (TGFβ) (182). The CSF levels of GDNF
has shown a significant increase in AD patients
(despite a decrease in serum levels of this growth
factor), which has been explained as an adaptive
process to enhance neurotrophic effect (183). Other
researchers have reported an increase in GDNF
plasma levels in AD patients (184). It has been
indicated that treatment with GDNF could protect
rabbits against AD-like symptoms, mainly by
increasing the expression level of anti-apoptotic
proteins (185). Also, transfection with GDNFexpressing gene using a lentiviral vector has
improved cognitive mechanisms in a transgenic

Antioxidant Therapies
There is significant evidence for involvement of
oxidative stress in the early stages of AD, as well as
activation of signaling pathways that contribute to
lesion formation and neuron degeneration (2). In
fact, oxidative stress and glycoxidation are closely
associated with AD development (196). Also, many
preclinical and small clinical studies have shown
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Vitamin A and Carotenoids: A lipid-soluble
antioxidant, vitamin A is synthesized in the body
from structurally more complex carotenoids in our
diet. Several studies have indicated a decrease in
plasma levels of vitamin A and α-carotene (but not
β-carotene) in AD patients compared to control
individuals (207). However, there have been reports
on the positive effect of β-carotene on cognitive
function (208), and a correlation between higher βcarotene plasma levels and memory in elderly
individuals (65-94 years old) (209). In 2004, Ono et
al. reported vitamin A and β-carotene would inhibit
the formation of β-amyloid fibrils in vitro, and even
destabilize already formed fibrils in a dosedependent manner (210). Also, vitamin A
deprivation could cause β-amyloid accumulation
(211) and memory deficit (212) in adult rodents.
The role of carotenoids in prevention of AD
symptoms and delaying of AD symptoms was
recently reviewed by Obulesu et al. (213).

that antioxidant drugs have significant effect on the
development of Alzheimer's disease. Reports show
antioxidants could contribute to breaking down
superoxide radicals and hydrogen peroxide
compounds, and prevent them from damaging the
neurons (197).
Vitamins
Vitamin E: As a free radical scavenger, alpha
tocopherol or vitamin E acts as an antioxidant and
has been studied in AD treatment. In 1996, Sano et
al. reported a randomized double-blind, placebocontrolled clinical study, which showed some
benefit for vitamin E administration to AD patients
(58% chance of death, institutionalization, change
to a Clinical Dementia Rating of three, or loss of
two basic activities of daily living within two years
for recipients of 2000 IU/day vitamin E compared
to 74% for patients who received placebo) (198). In
another clinical study published more than a decade
later, however, patients who received 800 IU
vitamin E per day and did show a reduction in
oxidative stress, no significant difference compared
to placebo group was observed in terms of MiniMental State Examination (MMSE) score after six
months (199). However, a recent meta-analysis of
different medical and dietary interventions in AD
patients has demonstrated a protective effect for
vitamin E (200). The potential effect of vitamin E
on cognitive function of AD patients was recently
reviewed by La Fata et al (201).

Vitamin B12: Low levels of vitamin B12 are
shown to be associated with neurodegenerative
disease and cognitive impairment (214). Metaanalysis studies indicate a lower level of vitamin
B12 in AD patients (215), and a recent study
indicates that administration of vitamin B12, along
with other vitamins, selenium, and phospholipids
could preserve synaptic function (216). In 2014, Li
et al. performed a systematic review and metaanalysis on efficacy of vitamin B supplementation
in AD (217). Their results did not confirm the
efficacy of vitamin B family in improving cognitive
function, and authors concluded that these vitamins
are unable to stabilize or slow decline in cognition
in AD patients.

Vitamin C: Ascorbic acid (vitamin C) is an
important antioxidant in intracellular functions,
with some of highest concentrations in CNS (202).
It easily reacts with reactive oxygen species to
neutralize their activity, and become ascorbate free
radical, which is then recycled (203). Vitamin C
seems to play an important role in neuronal repair,
generation of new cells, and expression of many
different genes (204). In a longitudinal study on 7193 years old Japanese-American men, the results
suggested that vitamin E and C supplement intake
might have a protective effect against vascular
dementia and may improve cognitive function in
elderly patients (205). More interestingly, the 2004
Cache County study indicates that only the
combination of vitamins C and E could reduce the
risk of AD (206).

Other Antioxidants
Omega 3 polyunsaturated fatty acids, e.g.,
eicosapentaenoic acid (ESA) and docosahexaenoic
acid (DHA) have been known to improve brain
function, and therefore, there has been suggestions
on their role in preventing neurodegenerative
diseases, including AD. In fact, insufficient DHA
intake has been related to brain aging, and reports
suggest a positive effect for DHA in delaying the
onset of AD (218). DHA is selectively accumulated
in synaptic membranes and oligodendrocytes (219).
A decrease in DHA brain levels in AD patients is
also reported (220). Several clinical studies indicate
beneficial effects of omega 3 in AD, which have
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systems with subsequent effects on Aβ and tau
pathology along with symptomatic effects, and
finally administration of various growth factors and
antioxidant therapy for promotion of neuronal
survival against a now-recognized wide-reaching
and complex neurodegenerative process. Many of
these molecules and approaches have been
promising enough to be advanced to human testing
in close to two thousand phase I-III clinical trials
with the most promising agents in these categories
reviewed in this article.
Despite this immense effort, no new drugs have
been approved for market, since the approval of
meantime in 2003. As reviewed in this article,
scientists have faced multiple challenges in this era
of failed AD drug development. Some challenges
were overcome by strategic drug design, as seen in
the development of active Aβ vaccines and the
challenge of overcoming cerebral vasogenic edema
caused by T-cell immunogenicity ultimately
accomplished by targeting smaller non-T-cell
immunogenic peptide sequences, or as seen in nonselective NOTCH inhibition in BACE-1 therapeutic
approaches which was overcome by design of
highly selective BACE-1 inhibitors. However,
despite careful honing of drug design, optimization
of pharmacodynamics and pharmacokinetics, and
significant modifications that introduced reduction
in toxicity, no new AD drugs have been found to
significantly affect clinical outcomes and delay
disease progression.
What are we doing wrong? While several
contributing factors may be responsible for the
continuous failure of clinical trials, one common
challenge that has continued to emerge and that all
drug development scientists must consider is the
timing of treatment and disease staging. Most
clinical trial study designs in the past two decades
have focused on administering treatment to patients
with mild-to-moderate AD and measuring for
improvement in symptoms or clinical outcomes as
measured by various cognitive scales, an approach
that worked well for acetylcholinesterase inhibitors
and memantine. However, these drugs targeted late
stage processes contributing to overall cognitive
symptoms with no effect on degenerative processes.
It is now well known that the etiologic and
neurodegenerative processes of AD start at least a
decade prior to the appearance of symptoms. At
symptom start then, there is likely already
significant irreversible neurodegeneration present.

been recently reviewed by Thomas et al (221).
Alkaloids, including caffeine, have also been
studied extensively for their potential effect on AD
progression. However, the results of observational
studies vary significantly, and are therefore
inconclusive (222). Gingko biloba, a natural plant
containing flavonoids and terpenoids, has both
antioxidant and anti-inflammatory properties, as
well as free radical scavenging ability, can reduce
amyloid precursor protein and inhibit Aβ
aggregation (223).
Metal chelators, glutathione peroxidases, SOD
enzymes, antioxidant enzyme MnSOD, repair
enzymes such as lipases, proteases, and DNA repair
enzymes play important roles in neuronal survival
and could protect brain tissue against oxidative
damage (2). Melatonin, a pineal gland hormone
with well-known role in sleep regulation, easily
passes BBB, is a scavenger of hydroxyl, carbonate,
alkoxyl, peroxyl and aryl cation radicals, and
stimulates activities of antioxidative enzymes,
which
suggests
a
protective
role
in
neurodegenerative disorders (224). It is also
hypothesized that the higher AD prevalence in
women could be related to reduction of estrogen in
postmenopausal stage (225). Xu et al meta-analysis
has also shown a protective role for estrogen in AD
(200).
CONCLUSION
It has long been recognized that the antiAlzheimer’s drugs currently available for treatment
modify only the late downstream effects of the AD
pathophysiologic process and only temporarily
reduces symptoms with no effect on disease
progression. Drug development scientists have
long sought therapeutic approaches that target the
etiologic processes of AD which can then
ultimately affect disease progression. The past two
decades has seen rapid growth in the understanding
of the underlying mechanisms involved in the
etiology of AD, including the role of Aβ and tau,
the role of various neurotransmitters, and the role of
growth factors and antioxidants. This has led to the
development and testing of hundreds of molecules
and numerous approaches targeted within these
mechanistic categories including active and passive
immunization against Aβ and tau, inhibition of Aβ
aggregation through BACE-1 and y-secretase
inhibition, modulation of various neurotransmitter
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itself can potentially affect the interaction of the
agent with intracellular mechanisms.
AD drug development has undergone rapid
growth in the past two decades. Despite the lack of
positive clinical trial outcomes, the lessons learned
with each trial and each failure have brought us
closer to a deeper understanding of the disease and
the drugs we are using to combat the disease. With
an armamentarium that has been finely honed to
optimize success, and the ability to now conduct
appropriately designed clinical trials, we are at the
dawn of a new era in the fight against this deadly
disease that has plagued humanity for centuries.

Furthermore, the diagnosis of AD is not made until
symptoms observably impair daily activities, at
which point even more severe neurodegeneration is
likely present. Drug development scientists are
increasingly recognizing that administering drug
therapy even in mild-to-moderate disease may be
too late to affect disease progression. For instance,
the EXPEDITION studies, which were the phase III
trials of the monoclonal antibody solanezumab, an
agent which was highly anticipated to be the most
successful of all agents ever in development, failed
to show benefit in the primary clinical outcome
measure when administered in patients with mild to
moderate AD. However, when only early disease
was evaluated (e.g mild AD), there was suggestion
toward some benefit in patients with only middle
disease. As such, we are increasingly seeing study
designs similar to that of the active vaccine CAD106, which is currently enrolling ApoE4 carriers
who are cognitively and will measure the ability to
delay diagnosis to MCI or AD dementia after 5
years of treatment. Studies of genetic forms of AD
are easier to design, conduct, and analyze than
studies of non-genetic forms of AD, as patient
ascertainment through genotyping provides a
reliable biomarker of likely AD development.
However, genetic AD is much less common than
non-genetic AD and design of clinical trials with
early ascertainment of patients with non-genetic AD
is absolutely necessary. Early patient ascertainment
with non-genetic forms of AD had previously been
difficult, due to the lack of reliable biomarkers
often leading to on-treatment groups containing
people that would never go on to develop the
disease anyways. With the development and
validation of the PET-ligand florbetapir, PET
amyloid imaging can now be utilized as a
biomarker in non-genetic forms of AD, allowing
more accurate ascertainment of patients who would
likely go on to develop AD for inclusion in clinical
trials prior to them actually meeting clinical criteria
for AD diagnosis. As such, agents such as
solanezumab and bapenzumab and most recently
the BACE inhibitor XYZ are enrolling or have
announced plans to enroll patients in re-designed
clinical trials that target patients with normal
cognitive function who are deemed at risk for AD
by PET amyloid imaging as inclusion criteria. This
recent trend in clinical trials shifts the participants
towards earlier disease and younger ages, which in
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